Document:

exv10w02

 

23 JANUARY 2006

TLS BETA PTE. LTD.

PHARMACO INVESTMENTS LTD

(formerly known as Transfarma Holdings Limited)

QUINTILES ASIA PACIFIC COMMERCIAL HOLDINGS, INC.

	 	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	AMENDED AND RESTATED
	 	 
	 

	 	SHAREHOLDERS’ AGREEMENT	 	 
	 
	 	 	 	 
	 

	 	 	 	 

 

 

CONTENTS

	 	 	 	 	 	 	 
	CLAUSE	 	 	 	PAGE
	1.	 	DEFINITIONS AND INTERPRETATION
	 	 	2	 
	1A.	 	AMENDMENT AND RESTATEMENT
	 	 	2	 
	2.	 	SHAREHOLDING IN AND PURPOSE OF HOLDCO
	 	 	2	 
	3.	 	SHAREHOLDING IN AND PURPOSE OF NEWCO1
	 	 	3	 
	4.	 	CORPORATE AUTHORISATIONS
	 	 	3	 
	5.	 	BOARD OF DIRECTORS
	 	 	3	 
	6.	 	BOARD MEETINGS
	 	 	4	 
	7.	 	BOARD COMMITTEES
	 	 	5	 
	8.	 	MANAGEMENT
	 	 	5	 
	9.	 	MEETING OF SHAREHOLDERS
	 	 	6	 
	10.	 	RESERVED MATTERS
	 	 	6	 
	11.	 	NEWCO2 PUT OPTION AND CALL OPTION MATTERS
	 	 	6	 
	12.	 	NEWCO3 PUT OPTION AND CALL OPTION MATTERS
	 	 	6	 
	13.	 	ISSUE OF SHARES
	 	 	7	 
	14.	 	FINANCING
	 	 	7	 
	15.	 	FINANCIAL MATTERS
	 	 	8	 
	16.	 	CONFIDENTIALITY
	 	 	8	 
	17.	 	RESTRICTIONS
	 	 	9	 
	18.	 	RIGHT OF FIRST PARTICIPATION
	 	 	12	 
	19.	 	REGULATORY MATTERS
	 	 	13	 
	20.	 	RELATIONSHIP WITH AFFILIATES
	 	 	13	 
	21.	 	TAX MATTERS
	 	 	15	 
	22.	 	NO SIDE VOTING AGREEMENTS
	 	 	15	 
	23.	 	UNDERTAKINGS AND WARRANTIES
	 	 	15	 
	24.	 	TRANSFER OF SHARES IN HOLDCO
	 	 	15	 
	25.	 	TRANSFER OF SHARES IN HOLDCO PURSUANT TO
DECLARATION OF AN EVENT OF DEFAULT UNDER
AMENDED AND RESTATED SHAREHOLDERS’ LOAN AGREEMENT
	 	 	18	 
	26.	 	CO-SALE RIGHTS
	 	 	19	 
	27.	 	DRAG ALONG RIGHTS
	 	 	19	 
	28.	 	DEADLOCK RESOLUTION
	 	 	19	 
	29.	 	DURATION AND TERMINATION
	 	 	21	 
	30.	 	REPRESENTATIONS AND WARRANTIES
	 	 	24	 
	31.	 	AGREEMENT RELATING TO INDIA
	 	 	25	 
	32.	 	SUPREMACY OF THIS AGREEMENT
	 	 	26	 
	33.	 	COSTS
	 	 	26	 
	34.	 	NO PARTNERSHIP OR AGENCY
	 	 	26	 
	35.	 	ENTIRE AGREEMENT
	 	 	26	 
	36.	 	MUTUAL CONSULTATION AND GOODWILL
	 	 	26	 
	37.	 	NOTICES
	 	 	26	 
	38.	 	ASSIGNMENT
	 	 	28	 
	39.	 	GOVERNING LAW AND ARBITRATION
	 	 	28	 
	40.	 	NO RIGHTS UNDER CONTRACTS (RIGHTS OF THIRD PARTIES) ACT (CAP. 53B)
	 	 	28	 
	41.	 	COUNTERPARTS
	 	 	28	 
	42.	 	FURTHER ASSURANCE
	 	 	28	 
	 	 	 
	 	 	 	 
	SCHEDULE 1 — INTERPRETATION	 	 	29	 
	SCHEDULE 2 — RESERVED MATTERS	 	 	33	 
	SCHEDULE 3 — EXCLUDED COMPETING BUSINESS (ZPH OR AFFILIATES)	 	 	35	 
	SCHEDULE 4 — EXCLUDED COMPETING BUSINESS (QTC OR AFFILIATES)	 	 	36	 
	 
	THE EXHIBIT — FORM OF DEED OF RATIFICATION AND ACCESSION	 	 	1	 

 

 

THIS AGREEMENT is made on 23 January 2006

Between:

	(1)	 	TLS BETA PTE. LTD. (Co. Reg. No. 200500368D), a company incorporated in Singapore and having
its registered office at 60B Orchard Road, #06-18 Tower 2 The Atrium @ Orchard, Singapore
238891 (TLS);

	(2)	 	PHARMACO INVESTMENTS LTD (formerly known as Transfarma Holdings Limited) (Co. Reg. No.
LL04247), a company incorporated in Labuan, Malaysia and having its registered office at
Brumby House, 1st Floor, Jalan Bahasa, 87011 Labuan, F.T. Labuan, Malaysia (PharmaCo); and

	(3)	 	QUINTILES ASIA PACIFIC COMMERCIAL HOLDINGS, INC. (Co. Reg. No. 807996), a corporation
incorporated in North Carolina, United States of America with its principal address at 4709
Creekstone Drive, Suite 200, Durham, NC 27703, United States of America (QIV).

Whereas:

(A) Pursuant to the Shareholders’ Agreement dated 28 January 2005 and made between TLS and PharmaCo
(Shareholders’ Agreement), (i) TLS and PharmaCo have jointly incorporated a private limited company
in Singapore known as Asia Pacific Pharmaceutical Holdings Pte. Ltd. (Co. Reg. No. 200501108N) with
its registered office at 150 Beach Road, #25-03/04 The Gateway West, Singapore 189720 (Holdco).
Holdco has an authorised capital of US$1,000,000 consisting of 1,000,000 ordinary shares of US$1
each. As at the date of this Agreement, the issued and paid up share capital of Holdco is US$6
consisting of 6 ordinary shares of US$1 each, with 3 ordinary shares registered in the name of each
of TLS and PharmaCo; and (ii) Holdco has incorporated a private limited company in Singapore known
as Asia Pacific Pharmaceutical Investments Pte. Ltd. (Co. Reg. No. 200503853W) with its registered
office at 150 Beach Road, #25-03/04 The Gateway West, Singapore 189720 (Newco1). Newco1 has an
authorised capital of US$1,000,000 consisting of 1,000,000 ordinary shares of US$1 each. The
issued and paid up share capital of Newco1 is US$1 consisting of 1 ordinary share of US$1
registered in the name of Holdco.

(B) The sale of all the issued shares in the capital of Newco2 (as defined below) (Newco2 Option
Shares) by PharmaCo to Holdco has been completed (Newco2 Completion) in accordance with the Put and
Call Option Agreement dated 28 January 2005 and made between PharmaCo, Holdco and TLS (Newco2 Put &
Call Option Agreement) as supplemented by a Supplemental Agreement dated 10 November 2005 and made
between PharmaCo, Holdco and TLS (First Supplemental Agreement).

(C) Pursuant to the Put and Call Option Agreement dated the same date as this Agreement and made
between QIV, Holdco, TLS and PharmaCo (Newco3 Put & Call Option Agreement), on completion (Newco3
Completion) of the sale of all the issued shares in the capital of Newco3 (as defined below)
(Newco3 Option Shares) by QIV to Holdco, Holdco will allot and issue to QIV such number of ordinary
shares in the capital of Holdco (each credited as fully paid) as shall result in TLS, PharmaCo and
QIV holding shares in Holdco in equal proportions in the enlarged share capital of Holdco on a
fully-diluted basis as at Newco3 Completion.

(D) TLS, PharmaCo and QIV agree that (i) they shall participate together in the ownership,
management and operation of Holdco in accordance with the terms of this Agreement; and (ii) their
relationship as shareholders in Holdco and the conduct of the business and affairs of Holdco and
the Newcos (as defined below), shall be governed by the terms of this Agreement.

Page 1

 

It is agreed as follows:

1. Definitions and Interpretation

1.1 Words and expressions used in this Agreement shall have the meanings set out in Schedule 1
unless the context requires otherwise.

1.2 The Schedules form part of this Agreement.

1.3 The Exhibit does not form part of this Agreement.

1A. Amendment And Restatement

1A.1 With effect from the date of this Agreement and subject to Clause 1A.2, the Shareholders’
Agreement shall be amended and restated by replacing it in its entirety with the terms of this
Agreement.

1A.2 Nothing in this Agreement shall affect any accrued rights or interests of TLS and PharmaCo
under the Shareholders’ Agreement existing immediately prior to the date of this Agreement.

2. Shareholding in and Purpose of Holdco

2.1 The Parties acknowledge and agree that Holdco has been incorporated in Singapore as a private
limited company under the Companies Act with an authorised capital of US$1,000,000 consisting of
1,000,000 ordinary shares of US$1 each. As at the date of this Agreement, the issued and paid up
share capital of Holdco is US$6 consisting of 6 ordinary shares of US$1 each, with 3 ordinary
shares registered in the name of each of TLS and PharmaCo. As soon as practicable, and in any
event, within 30 days after the date of this Agreement, the Parties shall procure that the issued
and paid up share capital of Holdco be increased to US$162 consisting of 162 ordinary shares of
US$1 each, with 65 ordinary shares registered in the name of TLS, 32 ordinary shares registered in
the name of QIV and 65 ordinary shares registered in the name of PharmaCo. On Newco3 Completion,
the Parties shall procure that the issued and paid up share capital of Holdco be increased to
US$195 consisting of 195 ordinary shares of US$1 each, registered in the name of the Parties in
equal proportions.

2.2 The business of Holdco shall be that of an investment holding company and such related
businesses thereto. The business of Holdco shall be conducted in the best interests of Holdco in
accordance with the general principles of the then current business plan approved by the Parties
and on sound commercial profit making principles with the aim of generating the maximum achievable
maintainable profits available for distribution.

2.3 As soon as practicable, and in any event, within 30 days after the date of this Agreement, the
Parties shall procure the passing of resolutions by the directors of Holdco in respect of convening
an extraordinary general meeting of Holdco (subject to the receipt of consents to short notice from
all the holders of the issued shares in the capital of Holdco) immediately following the conclusion
of the meeting of the directors for the purpose referred to in clause 2.4.

2.4 The Parties shall give consents to short notice in respect of such extraordinary general
meeting and shall attend and vote thereat in favour of the resolution (in such terms as may be
agreed between them) approving the amendments to the Articles of Holdco which shall reflect the
provisions of this Agreement to the extent permitted by law. In the event of any inconsistency
between the provisions of this Agreement and the Articles of Holdco, the provisions of this
Agreement shall prevail.

Page 2

 

3. Shareholding in and Purpose Of Newco1

3.1 The Parties acknowledge and agree that Newco1 has been incorporated in Singapore as a private
limited company under the Companies Act with an authorised capital of US$1,000,000 consisting of
1,000,000 ordinary shares of US$1 each. The issued and paid up share capital of Newco1 is US$1
consisting of 1 ordinary share of US$1, registered in the name of Holdco.

3.2 The business of Newco1 shall be to acquire patented and off-patent branded ethical research
based pharmaceutical products or interests in companies that own patented and off-patent branded
ethical research based pharmaceutical products and such related businesses thereto as may be agreed
in writing between the Parties. The business of Newco1 shall be conducted in the best interests of
Newco1 in accordance with the general principles of the then current business plan approved by the
Parties and on sound commercial profit making principles with the aim of generating the maximum
achievable maintainable profits available for distribution.

3.3 As soon as practicable, and in any event, within 30 days after the date of this Agreement, the
Parties shall procure the passing of resolutions of the directors of Newco1 in respect of convening
an extraordinary general meeting of Newco1 (subject to the receipt of the consent to short notice
from Holdco, the holder of all the issued shares in the capital of Newco1) immediately following
the conclusion of the meeting of the directors for the purpose referred to in clause 3.4.

3.4 The Parties shall procure that the consent to short notice in respect of such extraordinary
general meeting of Newco1 is given and the resolution (in such terms as may be agreed between them)
approving the amendments to the Articles of Newco1 which shall reflect the provisions of this
Agreement to the extent permitted by law is passed. In the event of any inconsistency between the
provisions of this Agreement and the Articles of Newco1, the provisions of this Agreement shall
prevail.

4. Corporate Authorisations

Each Party undertakes and warrants to the other Parties that it has obtained or will within 14 days
from the date of this Agreement obtain all corporate authorisations (including, if applicable,
shareholders’ approval) necessary to enable it to enter into and perform its obligations under the
Primary Transaction Documents.

5. Board of Directors

5.1 The Board of each Group Company shall be responsible for the overall direction, supervision and
management of such Group Company.

5.2 The Board of each Group Company shall initially consist of 6 directors, of which:

	(a)	 	2 shall be appointed by TLS, at least 1 of whom must have relevant experience and knowledge
in the pharmaceutical industry;

	(b)	 	2 shall be appointed by PharmaCo, at least 1 of whom must have relevant experience and
knowledge in the pharmaceutical industry; and

	(c)	 	2 shall be appointed by QIV, at least 1 of whom must have relevant experience and knowledge
in the pharmaceutical industry.

5.3 The shareholder of Holdco with the highest Shareholding Percentage shall be entitled to appoint
the chairman of each of the Group Companies.

5.4 Notwithstanding clause 5.3, the chairman of each of the Group Companies shall be appointed by
TLS, for so long as the Shareholding Percentage of TLS is at least 15% and if no other shareholder
of Holdco holds a higher Shareholding Percentage than TLS at that time. The right of TLS to appoint
the chairman under this clause 5.4 is personal to TLS and notwithstanding

Page 3

 

clause 24.10(c), shall not be assigned and transferred to the transferee of shares in Holdco held
by TLS unless such transferee is an affiliate of TLS.

5.5 The right of any Party under this Agreement to appoint a director to, or the chairman of, the
Board of each Group Company, shall include the right to remove such director or the chairman from
office at any time, and to determine from time to time the period during which such director or the
chairman shall be in office. Whenever a director or chairman ceases to hold office for whatever
reason, the Party who appointed (or would be entitled to appoint) such director or chariman shall
have the right to appoint another director or chairman in his stead.

5.6 Every appointment or removal of a director (or the chairman) by the relevant Party under this
Agreement shall be notified in writing to the other Parties and the company secretary of the
relevant Group Company. None of the Parties shall exercise its voting rights in the relevant Group
Company to oppose such appointment or removal.

6. Board Meetings

6.1 Unless otherwise agreed by a simple majority of directors of the relevant Board, all Board
meetings of each Group Company shall be held in its country of incorporation.

6.2 All meetings of the Board of each Group Company shall be convened and conducted in accordance
with the provisions of the Articles and the laws applicable to such Group Company.

6.3 The quorum for the transaction of business at any meeting of the Board of any Group Company
shall be 3 directors, of which at least 1 shall be appointed by each of TLS, PharmaCo and QIV,
present at the time when the relevant business is transacted.

6.4 In the event that a meeting of the Board of any Group Company duly convened cannot be held for
lack of a quorum, the meeting shall be adjourned to the same time and day of the following week and
at the same place and no notice need be given to the directors of such Group Company in relation to
such adjourned meeting. The quorum at an adjourned meeting of the Board of such Group Company shall
be 3 directors, of which at least 1 shall be appointed by each of TLS, PharmaCo and QIV, present at
the time when the relevant business is transacted.

6.5 The directors of each Group Company may meet together for the despatch of business, adjourn and
otherwise regulate their meetings as they think fit provided that notice has been given or
dispensed with in accordance with the Articles of such Group Company. Subject to clause 10,
questions arising at any meeting or adjourned meeting shall be decided by a majority of votes
provided that a quorum (determined in accordance with clauses 6.3 and 6.4) is present at any such
meeting or adjourned meeting. In case of an equality of votes, the chairman of the Board of such
Group Company shall not have a second or casting vote.

6.6 A resolution in writing signed by a majority of the directors for the time being of each Group
Company (who are not prohibited by the law or the relevant Articles from voting on such
resolutions) and constituting a quorum (determined in accordance with clause 6.3) shall be as
effective as a resolution passed at a meeting of the directors of such Group Company duly convened
and held, and may consist of several documents in the like form each signed by one or more
directors. All such resolutions shall, without delay, be forwarded or otherwise delivered to the
relevant company secretary to be recorded by him in the relevant company’s minute book. The
expressions in writing and signed include any writing or signature of any director delivered by
telefax or any form of electronic communication approved by the directors for such purpose from
time to time incorporating, if the directors deem necessary, the use of security and/or
identification procedures and devices approved by the directors.

6.7 A director of a Group Company may participate in a meeting of the Board of such Group Company
by means of a telephone conference, videoconferencing, audio visual, or other similar
communications equipment by means of which all persons participating in the meeting can hear

Page 4

 

one another, without a director being in the physical presence of another director or directors,
and participation in a meeting pursuant to this provision shall constitute presence in person at
such meeting. A director participating in a meeting in the manner aforesaid may also be taken into
account in ascertaining the presence of a quorum at the meeting. Such a meeting shall be deemed to
take place where the largest group of directors present for the purpose of the meeting is assembled
or, if there is no such group, where the chairman of the meeting is present.

6.8 A director of a Group Company shall be entitled at any time and from time to time to appoint
any person to act as his alternate and to terminate the appointment of such person and in that
connection the provisions of the Articles of such Group Company shall be complied with. Such
alternate director shall be entitled while holding office as such to receive notices of meetings of
the Board of such Group Company and to attend and vote as a director at any such meeting at which
the director appointing him is not present and generally to exercise all the powers, rights, duties
and authorities and to perform all functions of his appointor. Further, such alternate director
shall be entitled to exercise the vote of the director appointing him at any meeting of the Board
of such Group Company and if such alternate director represents more than one director, such
alternate director shall be entitled to one vote for every director he represents.

7. Board Committees

7.1 The Board of Holdco (but not the other Group Companies) for the time being may delegate any of
their powers to the following committees and such other committees as the Board of Holdco may deem
fit (Board Committees):

	(a)	 	an audit committee (Audit Committee);
	 
	(b)	 	a nominating and compensation committee (Nominating/Compensation Committee); and
	 
	(c)	 	an executive committee.

7.2 The number of members to be comprised in each of the Board Committees shall be determined by
the Parties provided that each Party shall be entitled to appoint an equal number of
representatives on each of the Board Committees. The chairman of the Audit Committee shall be
appointed by QIV for the first year, TLS for the second year and PharmaCo for the third year, and
thereafter, such appointment right shall be rotated among QIV, TLS and PharmaCo for every
subsequent year. The chairman of the Nominating/Compensation Committee shall be appointed by
PharmaCo for the first year and QIV for the second year, and thereafter, such appointment right
shall be rotated between PharmaCo and QIV for every subsequent year.

7.3 All decisions of each of the Audit Committee and the Nominating/Compensation Committee shall
require the affirmative votes of all the representatives from the Parties on such Board Committee.
The chairman of such Board Committee shall not have a second or casting vote at meetings of such
Board Committee.

7.4 The roles, responsibilities and powers of each Board Committee shall be determined by the Board
of Holdco.

8. Management

The day-to-day management of each Group Company shall be carried out by a senior management team of
such Group Company which shall comprise the chief executive officer, chief financial officer,
country managers and such other management team members as the Board of such Group Company may
appoint. The appointment of the chief executive officer and the chief financial officer of each
Group Company shall require the unanimous written approval of the representatives of the Parties on
the Board of such Group Company. The chief executive officer of each Group Company shall report
directly to the Board of such Group Company on strategic matters. The chief financial officer of
each Group Company shall implement accounting and control policies of such Group Company and ensure
their compliance. For the avoidance of doubt,

Page 5

 

the chief executive officer of a Group Company may be the same person as the chief executive
officer of any other Group Company, and the chief financial officer of a Group Company may be the
same person as the chief financial officer of any other Group Company.

9. Meeting of Shareholders

9.1 General meetings of shareholders in each Group Company shall take place in accordance with the
applicable provisions of the Articles of such Group Company on the basis that:

	(a)	 	in the case of Holdco, the quorum shall be 1 duly authorised representative of each Party and
in the case of each Newco, 1 person representing Holdco as may be authorised by the Board of
Holdco, being the corporation beneficially entitled to the whole of the issued capital of such
Newco;

	(b)	 	the notice of meeting shall set out an agenda identifying in reasonable detail the matters to
be discussed (unless the shareholders agree otherwise);
	 
	(c)	 	each shareholder shall have 1 vote for every ordinary share held by it; and
	 
	(d)	 	the chairman of the meeting shall not have a second or casting vote.

9.2 Any matters requiring a general meeting of or approval by the shareholders under the Companies
Act, but not covered by the Reserved Matters, shall be dealt with in accordance with the relevant
Memorandum and Articles.

10. Reserved Matters

Subject to clauses 11, 12, and 18.1(e) and any additional requirements specified by the Companies
Act or other applicable law, none of the Reserved Matters shall be taken by any Group Company
unless the prior written approvals of each Party (so long as it has a Shareholding Percentage of at
least 5%) and all the Significant Shareholders have been obtained. For the avoidance of doubt, the
Parties shall be deemed to have given their respective prior written approval for those Reserved
Matters which are or will be done to give effect to the matters contemplated under any of the
Primary Transaction Documents.

11. Newco2 Put Option And Call Option Matters

Notwithstanding anything to the contrary, on and from Newco2 Completion, all decisions relating to
any matter under the Supplemented Newco2 Put & Call Option Agreement as between Holdco and PharmaCo
including but not limited to: (a) the commencement, settlement, defence or abandonment of
litigation or admission of liability in relation to any matter under the Supplemented Newco2 Put &
Call Option Agreement; and (b) the exercise of any right or performance of any obligation by Holdco
under the Supplemented Newco2 Put & Call Option Agreement, shall be determined by TLS and QIV, and
PharmaCo shall at its election either (i) exercise its votes in Holdco to give effect to the
directions of TLS and QIV in relation thereto, or (ii) abstain from voting on such matter and
permit TLS and QIV to direct the action of Holdco in relation thereto provided that such abstention
shall not have the effect of preventing Holdco from carrying out TLS’ and QIV’s instructions.
PharmaCo shall perform all acts and take all steps necessary on its part to ensure that Holdco will
give effect to TLS’ and QIV’s directions under this clause provided that PharmaCo shall not be
obliged to perform any acts or take any steps which derogates from the right of PharmaCo to abstain
from voting (where permitted herein) on such matter.

12. Newco3 Put option And Call Option Matters

12.1 Notwithstanding anything to the contrary, prior to Newco3 Completion, all decisions relating
to any matter under the Newco3 Put & Call Option Agreement as between Holdco and QIV including but
not limited to: (a) the fulfilment of the conditions precedent for exercise of the

Page 6

 

put option or call option under the Newco3 Put & Call Option Agreement (save for the condition
precedent under (i) clause 7.1(c) of the Newco3 Put & Call Option Agreement which shall be
determined by TLS and PharmaCo jointly and (ii) clause 7.1(l) of the Newco3 Put & Call Option
Agreement which shall be determined by QIV solely); (b) the decision whether to exercise the put
option or the call option under the Newco3 Put & Call Option Agreement; (c) the commencement,
settlement, defence or abandonment of litigation or admission of liability in relation to any
matter under the Newco3 Put & Call Option Agreement; and (d) the exercise of any right or
performance of any obligation by Holdco under the Newco3 Put & Call Option Agreement, shall be
determined by TLS solely, and each of QIV and PharmaCo shall at its election either (i) exercise
its votes in Holdco to give effect to the directions of TLS in relation thereto, or (ii) abstain
from voting on such matter and permit TLS to direct the action of Holdco in relation thereto
provided that such abstention shall not have the effect of preventing Holdco from carrying out TLS’
instructions. Each of QIV and PharmaCo shall perform all acts and take all steps necessary on its
part to ensure that Holdco will give effect to TLS’ directions under this clause provided that it
shall not be obliged to perform any acts or take any steps which derogates from its right to
abstain from voting (where permitted herein) on such matter.

12.2 Notwithstanding anything to the contrary, on and from Newco3 Completion, all decisions
relating to any matter under the Newco3 Put & Call Option Agreement as between Holdco and QIV
including but not limited to: (a) the commencement, settlement, defence or abandonment of
litigation or admission of liability in relation to any matter under the Newco3 Put & Call Option
Agreement; and (b) the exercise of any right or performance of any obligation by Holdco under the
Newco3 Put & Call Option Agreement, shall be determined by TLS and PharmaCo, and QIV shall at its
election either (i) exercise its votes in Holdco to give effect to the directions of TLS and
PharmaCo in relation thereto, or (ii) abstain from voting on such matter and permit TLS and
PharmaCo to direct the action of Holdco in relation thereto provided that such abstention shall not
have the effect of preventing Holdco from carrying out TLS’ and PharmaCo’s instructions. QIV shall
perform all acts and take all steps necessary on its part to ensure that Holdco will give effect to
TLS’ and PharmaCo’s directions under this clause provided that QIV shall not be obliged to perform
any acts or take any steps which derogates from the right of QIV to abstain from voting (where
permitted herein) on such matter.

13. Issue of Shares

The share capital of Holdco may be increased from time to time by such amount as the Parties may
agree provided that the issue of any unissued shares or of any new shares from time to time created
in the capital of Holdco shall before issuance be offered for subscription in the first instance to
each Party in its Shareholding Percentage, unless otherwise agreed by the Parties in writing.

14. Financing

14.1 The Parties shall extend shareholders’ loans of up to US$195,000,000 to Holdco, on the terms
of the Amended and Restated Shareholders’ Loan Agreement.

14.2 In the event that the Parties determine that further financing requirements of each Group
Company shall be provided by way of external borrowings from third parties, each Party shall use
its reasonable endeavours to procure that commercial loans and other loans from banks or other
financial institutions, or other sources, be made to such Group Company.

14.3 None of the Parties shall be obliged to participate for the benefit of any Group Company in
any guarantee, bond or financing arrangement with any bank or financial institution, whether as a
guarantor or in any other capacity whatsoever. If and to the extent that the Parties unanimously
agree in writing to participate in any such guarantee, bond or financing arrangement then, unless
the Parties agree otherwise in writing, any liability or obligation to be assumed by them in
relation to any such guarantee, bond or financing arrangement shall be borne in proportion to their
Shareholding Percentages. Any such liability or obligation shall be several and not joint or joint
and several, unless they agree otherwise in writing.

Page 7

 

14.4 Immediately upon the disposal by any Party of all its shareholding interest in Holdco pursuant
to this Agreement (other than pursuant to clause 25), that Party shall be released from its
financing obligations under clauses 14.1 and 14.2 and the shareholders’ loans extended or to be
extended by such Party to any Group Company shall be dealt with in accordance with clause 24.10.
The Parties shall within 30 days after the disposal by any Party of all its shareholding interest
in Holdco take all necessary steps to discharge any security or guarantee issued by that Party in
connection with the indebtedness of any Group Company. However, a Party who ceases to be a
shareholder of Holdco shall remain liable under any guarantee or security for any claims arising
out of any default by such Group Company during the period in which that Party was still a
shareholder in Holdco.

15. Financial Matters

15.1 The Parties shall procure that each Group Company adopts accounting principles approved by the
Board of such Group Company in relation to its financial statements.

15.2 The Parties shall each use its best endeavours to procure that the Board of each Group Company
shall, after making proper provisions and subject to the appropriation of prudent and proper
reserves and the retention out of profits of funds to meet working capital requirements and other
expenditure proposed under any business plans, distribute to its shareholders the maximum amount of
dividends, such dividends being declared and paid to its shareholders within three months from the
end of that financial year or any time within that financial year as may be agreed by its
shareholders.

15.3 The Parties shall procure that each Group Company gives access to the Parties to examine the
books, records and accounts kept by such Group Company and provides each Party all information,
including monthly management accounts and operating statistics and other trading and financial
information, in such form as a Party reasonably requires to keep it properly informed about the
business and affairs of such Group Company and generally to protect its interests as a shareholder
in Holdco.

15.4 Without prejudice to the generality of clause 15.3, the Parties shall procure that each Group
Company supplies the Parties with copies of:

	(a)	 	audited accounts for such Group Company (complying with all relevant legal requirements);
	 
	(b)	 	a business plan and itemised revenue and capital budgets for each financial year showing
proposed trading and cash flow figures, manning levels and all material proposed acquisitions,
disposals and other commitments for that financial year; and
	 
	(c)	 	monthly/quarterly management accounts of such Group Company, which shall include a
consolidated profit and loss account, balance sheet and cash flow statement broken down
according to the principal divisions of such Group Company.

16. Confidentiality

16.1 Subject to the provisions of clause 16.2 below, each of the Parties shall both during and
after the term of this Agreement:

	(a)	 	keep confidential the terms of this Agreement and all information, whether in writing or any
other form, which it may acquire in relation to each Group Company or in relation to the
clients, business or affairs of each of the other Parties (or any of its affiliates) and shall
not use or disclose such information except with the prior written consent of such other
Party(ies); and

	(b)	 	procure that its subsidiaries and its officers, employees and representatives and those of
its subsidiaries observe a similar duty of confidentiality.

Page 8

 

16.2 The restriction in clause 16.1 does not apply to any information which:

	(a)	 	at the time of supply is already in the public domain;
	 
	(b)	 	subsequently comes into the public domain, other than through a breach of any duty of
confidentiality by any Party;
	 
	(c)	 	is already in the lawful possession of the Party receiving the information (or its authorised
recipient);
	 
	(d)	 	subsequently comes into the lawful possession of the Party receiving the information (or its
authorised recipient) from a third party who is not in breach of any duty of confidentiality
with regard to the information;
	 
	(e)	 	is required to be disclosed by law, or by any stock exchange or governmental or regulatory
authority having jurisdiction over the Party required to disclose the information, as long as
the disclosing Party first consults the other Parties (where reasonably practicable) on the
proposed form, timing, nature and purpose of the disclosure;
	 
	(f)	 	has been independently acquired by any Party otherwise than in the exercise of that Party’s
rights under this Agreement or in the implementation of this Agreement;
	 
	(g)	 	in order to perform its obligations under or pursuant to this Agreement any Party is required
to disclose to a third party; or
	 
	(h)	 	relates to any Group Company and is disclosed in the ordinary course of advancing its
business.

16.3 If a Party ceases to be a shareholder in Holdco, it shall (if required by notice from any
Group Company or any other Party) return to such Group Company or other Party (as the case may be)
the confidential information of such Group Company or other Party (as the case may be). If so
required to return confidential information, the first Party shall (and shall ensure that its
subsidiaries and its officers and employees and those of its subsidiaries shall):

	(a)	 	return all documents containing confidential information which have been provided by or on
behalf of such Group Company or other Party (as the case may be) demanding the return of
confidential information; and

	(b)	 	destroy any copies of such documents and any document or other record reproducing, containing
or made from or with reference to the confidential information,

(save, in each case, for any submission to or filings with governmental, tax or regulatory
authorities). The first Party shall return or destroy the confidential information as soon as
practicable after receiving notice to do so.

16.4 The provisions of this clause 16 shall survive the termination of this Agreement.

17. Restrictions 

17.1 Each of PharmaCo and QIV shall not and shall procure that each of its affiliates shall not
(whether alone or jointly with another and whether directly or indirectly) carry on or be engaged
or (except as the owner for investment of securities dealt in on a stock exchange and not exceeding
5% in nominal value of the securities of any class) interested economically or otherwise in any
manner whatsoever in Competing Business I (as defined below) for so long as it owns at least 5% of
the issued share capital in Holdco and for a period of 2 years after it ceases to own at least 5%
of the issued share capital in Holdco.

Page 9

 

17.2 On and from Newco2 Completion, PharmaCo shall not and shall procure that its affiliates shall
not (whether alone or jointly with another and whether directly or indirectly) carry on or be
engaged or (except as the owner for investment of securities dealt in on a stock exchange and not
exceeding 5% in nominal value of the securities of any class) interested economically or otherwise
in any manner whatsoever in Competing Business II (as defined below) for so long as its owns at
least 5% of the issued share capital in Holdco and for a period of 2 years after it ceases to own
at least 5% of the issued share capital in Holdco.

17.3 On and from Newco3 Completion, QIV shall not and shall procure that its affiliates shall not
(whether alone or jointly with another and whether directly or indirectly) carry on or be engaged
or (except as the owner for investment of securities dealt in on a stock exchange and not exceeding
5% in nominal value of the securities of any class) interested economically or otherwise in any
manner whatsoever in Competing Business III (as defined below) for so long as its owns at least 5%
of the issued share capital in Holdco and for a period of 2 years after it ceases to own at least
5% of the issued share capital in Holdco.

17.4 The restrictions in clauses 17.1 to 17.3 shall not apply to:

	(a)	 	any agency or contract sales organisation contracts or arrangements which the Group Companies
do not wish to undertake;

	(b)	 	QIV and its affiliates acquiring any right, title or interest in or to, directly or
indirectly, Existing Tail-end Products (as defined below) in any one or more of the Asia
Pacific Countries (as defined below) so long as the transaction in respect of any such
acquisition (Relevant Transaction) also involves the acquisition of any right, title or
interest in or to, directly or indirectly, Existing Tail-end Products in both an Asia Pacific
Country and another country. For the avoidance of doubt, the restriction set forth in clause
17.1 will only apply if any acquisition described in this sub-paragraph (b) relates solely to
Existing Tail-end Products in one or more Asia Pacific Country(ies); and

	(c)	 	QIV and its affiliates acquiring any right, title or interest in or to, directly or
indirectly, Novel Products (as defined below) anywhere in the world (Novel Products
Transaction).

17.5 For the purposes of this Agreement:

	(a)	 	Competing Business I means the business of acquiring any right, title or interest in or to,
directly or indirectly, patented and off-patent branded ethical research based pharmaceutical
products, carried on by Holdco and/or any of its subsidiaries in the following countries:
Thailand, the People’s Republic of China, Hong Kong, Macau, Taiwan, Indonesia, Singapore,
Brunei, Cambodia, Vietnam, Malaysia, the Philippines, India, Korea, Australia and New Zealand
(each an Asia Pacific Country and collectively referred to as Asia Pacific Countries);

	(b)	 	Competing Business II means the business of providing (i) marketing services for patented and
off-patent branded ethical research based pharmaceutical and healthcare products through
agency or contract sales organisation (CSO) arrangements and (ii) regulatory services
including advisory services on regulatory environment, activities pertaining to the
registration of patented and off-patent branded ethical research based pharmaceutical and
healthcare products with the relevant regulatory bodies and product licence holding, market
research services and sales and marketing development programmes carried on by Newco2 and its
subsidiaries and (after Newco3 Completion) Newco3 and its subsidiaries. For the avoidance of
doubt, Competing Business II does not include any business set out in Schedule 3 and then
being carried on by ZPH or its affiliates;

	(c)	 	Competing Business III means the business of providing (i) marketing services for patented
and off-patent branded ethical research based pharmaceutical and healthcare

Page 10

 

	 	 	products through agency or contract sales organisation (CSO) arrangements and (ii)
regulatory services including advisory services on regulatory environment, activities
pertaining to the registration of patented and off-patent branded ethical research based
pharmaceutical and healthcare products with the relevant regulatory bodies and product
licence holding, market research services and sales and marketing development programmes
carried on by Newco2 and its subsidiaries and Newco3 and its subsidiaries. For the
avoidance of doubt, Competing Business III does not include any business set out in
Schedule 4 and then being carried on by QTC or its affiliates;

	(d)	 	Existing Tail-end Products means patented and off-patent branded ethical research based
pharmaceutical and healthcare products that have been approved and are available for sale in
any Asia Pacific Country for at least six years (both after and before the date of this
Agreement); and
	 
	(e)	 	Novel Product means any pharmaceutical product which is not an Existing Tail-end Product.

17.6 In the event that there is any dispute between the Parties in respect of the scope of
Competing Business I, Competing Business II or Competing Business III, the Parties shall for a
period of 30 days in good faith negotiate and endeavour to resolve such dispute amicably.

17.7 Each Party shall not and shall procure that each of its affiliates shall not for so long as it
owns at least 5% of the issued share capital in Holdco and for a period of 2 years after it ceases
to own at least 5% of the issued share capital in Holdco (Restricted Period) directly or
indirectly, solicit or endeavour to entice away from any Group Company or any of their subsidiaries
any person employed by any of such companies during the Restricted Period in skilled or managerial
work. The placing of an advertisement of a post available to a member of the public generally and
the recruitment of a person through an employment agency shall not constitute a breach of this
clause 17.7 provided that such Party or any of its affiliates does not encourage or advise such
agency to approach any such employee.

17.8 QIV shall procure that QTC shall not, for a period of 5 years from the date of Newco3
Completion, sell, assign, transfer, grant any licence or otherwise confer any right whatsoever in
the trademark “Innovex” to any person engaged in or carrying on the business of providing (a)
marketing services for patented and off-patent branded ethical research based pharmaceutical and
healthcare products through agency or contract sales organisation (CSO) arrangements and (b)
regulatory services including advisory services on regulatory environment, activities pertaining to
the registration of patented and off-patent branded ethical research based pharmaceutical and
healthcare products with the relevant regulatory bodies and product licence holding, market
research services and sales and marketing development programmes, in the case of each of
sub-clauses (a) and (b), in any Asia Pacific Country.

17.9 Unless the Parties otherwise agree in writing, the Parties shall procure that the name and
trademark “Innovex” licensed by QTC and/or subsidiaries of QTC engaged in Quintiles’ Business to
Newco3 and/or its subsidiaries pursuant to the Newco3 Put & Call Option Agreement shall not be used
by Holdco or any of its subsidiaries for businesses other than the business of providing (a)
marketing services for patented and off-patent branded ethical research based pharmaceutical and
healthcare products through agency or contract sales organisation (CSO) arrangements and (b)
regulatory services including advisory services on regulatory environment, activities pertaining to
the registration of patented and off-patent branded ethical research based pharmaceutical and
healthcare products with the relevant regulatory bodies and product licence holding, market
research services and sales and marketing development programmes worldwide other than in the
Americas (including North and South America, and all of the United States), Europe (Western,
Eastern and Central), Africa and Japan. For the avoidance of doubt, Holdco and/or any of its
subsidiaries may not use the trademark “Innovex” for any business for the provision of clinical
development and related services and/or regulatory advisory services relating to product
development in any country in the world.

Page 11

 

17.10 Each of the Parties acknowledges and agrees that:

	(a)	 	each of clauses 17.1 to 17.3 and 17.7 to 17.9 constitutes an entirely separate and
independent restriction and that the duration, extent and application of each restriction are
no greater than is reasonable and necessary for the protection of the interests of the other
Parties and the Group Companies. If any such restriction shall be adjudged by any court or
authority of competent jurisdiction to be void or unenforceable but would be valid if deleted
in part, or reduced in application, then the said restriction shall apply within the
jurisdiction of that court or competent authority with such modification as may be necessary
to make it valid and enforceable; and

	(b)	 	a breach of any of the covenants in clauses 17.1 to 17.3 and 17.7 to 17.9 would result in
harm to the other Parties and the Group Companies that cannot be adequately compensated by
monetary awards. Accordingly, it is agreed that in addition to all other remedies available to
the other Parties and the Group Companies at law or in equity, the other Parties and/or any of
the Group Companies shall be entitled to apply to a court of competent jurisdiction for relief
by way of restraining order, injunction, decree or otherwise, as may be appropriate to ensure
compliance with such covenants.

18. Right Of First Participation

18.1 In respect of the acquisition of Existing Tail-end Products pursuant to a Relevant Transaction
which also incorporates a service component, QIV agrees that it shall grant Newco1 the right of
first refusal to participate in any acquisition by it or its affiliates of any right, title or
interest in or to, directly or indirectly, such Existing Tail-end Products in any Asia Pacific
Country in accordance with the following principles:

	(a)	 	QIV shall inform the relevant principal of such right of first refusal of Newco1 in respect
of Existing Tail-end Products in the Asia Pacific Countries and shall use its reasonable
endeavours to negotiate with the relevant principal to permit disclosure to and discussion
with Newco1 on the Relevant Transaction in any Asia Pacific Country subject to Newco1 being
bound by confidentiality undertakings;

(b) QIV shall be entitled to carry out all negotiations in respect of the Relevant Transaction;

	(c)	 	QIV shall consult with Newco1 (as far as possible) beforehand in respect of the terms of the
Relevant Transaction relating to the acquisition of the Existing Tail-end Products in an Asia
Pacific Country and pursuant to such consultation, shall agree to the reasonable requests of
Newco1 in respect of such terms, subject to sub-paragraph (a) above;

	(d)	 	the percentage and/or quantum of Newco1’s participatory interest in the Relevant Transaction
in any Asia Pacific Country shall be determined by Newco1; and

	(e)	 	the approval of QIV shall not be required in connection with the decision of Newco1 on any
matter in relation to the Relevant Transaction (including but not limited to the decision
whether Newco1 should proceed in participating in the acquisition of the subject of the
Relevant Transaction, the percentage and/or quantum of Newco1’s participatory interest and the
terms of the Relevant Transaction), notwithstanding that such decision is a Reserved Matter.

18.2 In respect of the acquisition of Novel Products pursuant to a Novel Products Transaction, QIV
agrees that it shall invite Newco1 to participate (but not negotiate) together with QIV and/or its
affiliates in any acquisition by it or its affiliates of any right, title or interest in or to,
directly or indirectly, such Novel Products in any Asia Pacific Country. The terms of Newco1’s
participation are to be agreed between QIV and/or its affiliates and Newco1 in good faith
(including, for the avoidance of doubt, the percentage and/or quantum of Newco1’s participatory
interest).

Page 12

 

19. Regulatory matters

19.1 The Parties shall co-operate with each other to ensure that all information necessary or
desirable for making (or responding to any requests for further information following) any
notification or filing made in respect of this Agreement, or the transactions contemplated by it,
is supplied to the Party dealing with such notification and filing and that they are properly,
accurately and promptly made.

19.2 If any material action is taken or threatened by any court of competent jurisdiction or
government or regulatory authority prohibiting or restricting the businesses contemplated to be
carried on by any Group Company and the transactions contemplated under this Agreement, the Parties
shall promptly meet to discuss:

	(a)	 	the situation and the action to be taken as a result; and

	(b)	 	whether any modification to the terms of this Agreement (or any agreement entered into
pursuant to this Agreement) should be made in order that any requirement (whether as a
condition of giving any approval, clearance or consent or otherwise) of any regulatory
authority may be reconciled with, and within the intended scope of, the business arrangements
contemplated by this Agreement. The Parties shall co-operate to give effect to any agreed
modifications.

20. Relationship with Affiliates

20.1 Each Party shall ensure that any contracts between any Group Company and any affiliate of such
Party are made on an arm’s length commercial basis and on terms that are not unfairly prejudicial
to the interests of any of the Parties or such Group Company. Each Party will use all reasonable
endeavours to ensure that such terms are negotiated and settled in good faith.

20.2 The Parties agree that Pharma Industries, the contract manufacturing division of ZPH, shall be
the preferred provider (as defined below) of contract manufacturing services for Newco2 and Newco3.
For the purposes of this clause 20.2, preferred provider status means that the relevant party
shall first negotiate in good faith for a reasonable period with the relevant service provider to
agree on mutually satisfactory customary terms and conditions for the services to be provided and
only if the relevant parties fail to mutually agree on such terms and conditions shall the relevant
party obtain the services of third party service providers.

20.3 For so long as it owns at least 5% of the issued share capital in Holdco, PharmaCo shall
procure that ZPH and QIV shall procure that QTC grants Newco2 or Newco3 (as the case may be):

	(a)	 	exclusive marketing rights to market, sell, promote and distribute patented and off-patent
branded ethical research based pharmaceutical and healthcare products owned or acquired by ZPH
or QTC or their respective affiliates (as the case may be) through agency contracts in any
Asia Pacific Country; and

	(b)	 	exclusive marketing rights for marketing of patented and off-patent branded ethical research
based pharmaceutical and healthcare products owned or acquired by ZPH or QTC or their
respective affiliates (as the case may be) through contract sales organisation contracts in
any Asia Pacific Country,

on customary terms and conditions to be negotiated and agreed by the relevant parties in good
faith, and provided that the terms provided by Newco2 or Newco3 (as the case may be) are
commercially competitive.

20.4 In the event that (a) Newco3 and/or its subsidiaries require distribution services in their
countries of operation and/or (b) Newco2 and/or its subsidiaries require distribution services in
countries of operation not covered under the Newco2 Distribution Agreement, PharmaCo shall procure
that ZPH and/or its subsidiaries and the Parties shall procure that Newco3 and/or its

Page 13

 

subsidiaries or Newco2 and/or its subsidiaries (as the case may be) enter into a distribution
agreement (incorporating the following terms and such other terms as shall be agreed between the
Parties) pursuant to which ZPH and/or its subsidiaries agree to provide to Newco3 and/or its
subsidiaries or Newco2 and/or its subsidiaries (as the case may be) with distribution services
(Relevant Distribution Agreement):

	(a)	 	for so long as PharmaCo holds at least 5% of the shares in the issued share capital of
Holdco, Newco3 and/or its subsidiaries or Newco2 and/or its subsidiaries (as the case may be)
shall grant to ZPH and/or its subsidiaries an exclusive distribution contract in such
countries of operation where ZPH and/or its subsidiaries provide(s) distribution services;

	(b)	 	the rates offered by ZPH and/or its subsidiaries to Newco3 and/or its subsidiaries or Newco2
and/or its subsidiaries (as the case may be) are on a “most favoured” basis for similar sized
accounts and shall continue for so long as PharmaCo’s shareholding in Holdco does not fall
below 5%;

	(c)	 	ZPH will disclose fully to Holdco the basis on which it arrives at the “most favoured” rates
that Newco3 and/or its subsidiaries or Newco2 and/or its subsidiaries (as the case may be) are
charged, including the schedules of rates/charges for various customers (on a no-names basis);

	(d)	 	in the event that Holdco, Newco2 or Newco3 is subsequently listed, the Relevant Distribution
Agreement shall continue but may require certain amendments to be made thereto to comply with
relevant listing rules on, inter alia, related party transactions;

	(e)	 	the distribution terms for the first two years of the term of the Relevant Distribution
Agreement shall be on a “most favoured” basis for similar sized accounts; and

	(f)	 	after the first two years of the term of the Relevant Distribution Agreement, the
distribution terms will be negotiated in good faith on a “most favoured” basis for similar
sized accounts.

20.5 In the event that Newco2, Newco3 and/or any of their respective subsidiaries require(s)
clinical trial services or services for the development of pharmaceutical products prior to such
pharmaceutical products being initially marketed or re-marketed (Clinical Trial Services) in their
countries of operation, QIV shall procure that QTC and/or its subsidiaries and the Parties shall
procure that Newco2, Newco3 and/or any of their respective subsidiaries (as the case may be) enter
into a clinical trial services agreement (incorporating the following terms and such other terms as
shall be agreed between the Parties) pursuant to which QTC and/or its subsidiaries agree to provide
to Newco2, Newco3 and/or any of their respective subsidiaries (as the case may be) with Clinical
Trial Services (Relevant Clinical Trial Agreement):

	(a)	 	for so long as QIV holds at least 5% of the shares in the issued share capital of Holdco,
Newco2, Newco3 and/or any of their respective subsidiaries (as the case may be) shall grant to
QTC and/or its subsidiaries an exclusive clinical trial services agreement in such countries
of operation where QTC and/or its subsidiaries provide(s) Clinical Trial Services;

	(b)	 	the rates offered by QTC and/or its subsidiaries to Newco2, Newco3 and/or any of their
respective subsidiaries (as the case may be) are on a “most favoured” basis for similar sized
accounts and shall continue for so long as QIV’s shareholding in Holdco does not fall below
5%;

	(c)	 	QTC will disclose fully to Holdco the basis on which it arrives at the “most favoured” rates
that Newco2, Newco3 and/or any of their respective subsidiaries (as the case may be) are
charged, including the schedules of rates/charges for various customers (on a no-names basis);

Page 14

 

	(d)	 	in the event that Holdco, Newco2 or Newco3 is subsequently listed, the Relevant Clinical
Trial Agreement shall continue but may require certain amendments to be made thereto to comply
with relevant listing rules on, inter alia, related party transactions;

	(e)	 	the terms for the first two years of the term of the Relevant Clinical Trial Agreement shall
be on a “most favoured” basis for similar sized accounts; and

	(f)	 	after the first two years of the term of the Relevant Clinical Trial Agreement, the terms
will be negotiated in good faith on a “most favoured” basis for similar sized accounts.

21. Tax Matters

Each Party agrees to co-operate, and ensure that its subsidiaries co-operate, to such extent as may
be reasonably requested in connection with the making of any returns, claims or elections for
taxation purposes by any Group Company or otherwise in relation to the taxation affairs of any
Group Company.

22. No Side Voting Agreements

Each of the Parties shall not and shall procure that their respective affiliates shall not enter
into any side agreements with any of the other Parties or their affiliates to agree on the manner
in which any Party’s voting rights in Holdco should be exercised.

23.

Undertakings and Warranties

23.1 PharmaCo undertakes and warrants to the other Parties that it is at the date of this Agreement
and shall for so long as it is a shareholder in Holdco remain, a direct or indirect wholly-owned
subsidiary of ZPH (or any successor of ZPH) or an entity that directly or indirectly controls ZPH
(or any successor of ZPH).

23.2 TLS undertakes and warrants to the other Parties that it is at the date of this Agreement and
shall for so long as it is a shareholder in Holdco remain, a direct or indirect wholly-owned
subsidiary of Temasek Capital (Private) Limited (or any successor of Temasek Capital (Private)
Limited) or an entity that directly or indirectly controls Temasek Capital (Private) Limited (or
any successor of Temasek Capital (Private) Limited).

23.3 QIV undertakes and warrants to the other Parties that it is at the date of this Agreement, and
shall for so long as it is a shareholder in Holdco remain, a direct or indirect wholly-owned
subsidiary of QTC (or any successor (by any method) to all or substantially all of QTC’s assets or
business, as constituted on the date of such succession (a QTC Successor)) or persons that directly
or indirectly control QTC (or any QTC Successor); provided, however, QTC (or any QTC Successor) or
any affiliates of QTC (or any QTC Successor) may engage in any public offerings of securities and
participate in any distribution of securities related to any such public offerings without
breaching this undertaking or warranty.

23.4 QIV undertakes and warrants to the other Parties that on and from Newco3 Completion, QTC
either has no operation of Quintiles’ Business or has ceased operation of Quintiles’ Business in
the Asia Pacific Countries.

23.5 PharmaCo undertakes and warrants to the other Parties that on and from Newco2 Completion, ZPH
either has no operation of the PharmaLink Business or has ceased operation of the PharmaLink
Business in the Asia Pacific Countries.

24. Transfer of Shares in Holdco

24.1 A Party shall not transfer its shares in Holdco otherwise than in accordance with this
Agreement and the Articles. A Party shall not transfer all or any of its shares in Holdco until 30
days after the earlier of (a) Newco3 Completion and (b) the expiry of the QIV Put Option and TLS

Page 15

 

and PharmaCo Call Option in relation to the shares in Holdco held by QIV under the Newco3 Put &
Call Option Agreement. Provided that the provisions in this clause 24 shall not apply to (i) a
transfer of QIV’s shares in Holdco pursuant to the exercise of the QIV Put Option or TLS and
PharmaCo Call Option and (ii) a transfer of any Party’s shares in Holdco pursuant to clause 25.

24.2 Unless otherwise provided, a Party shall not sell, encumber or dispose of all or any part of
its shareholding interest in Holdco without the prior written consent of the other Parties.

24.3 Any share in Holdco may be transferred by a Party to any of its affiliates, and the
restrictions set out below (other than clause 24.10) shall not apply to any transfer of shares in
Holdco in these circumstances provided nevertheless that such affiliate may re-transfer such shares
to the original transferor or an affiliate of the original transferor and provided further that all
of such shares shall forthwith be re-transferred to the original transferor if at any time after
such transfer of shares, the transferee ceases to be an affiliate of the original transferor other
than as a result of public offerings of securities or related distributions as described in clause
23.3. Notwithstanding anything to the contrary in this Agreement, such transfer of shares shall not
relieve or discharge the transferor from any of its obligations under this Agreement and the
transferor shall continue to be subject to the obligations under this Agreement and be liable to
the other Parties as if no such transfer had occurred and the liability of the transferor hereunder
shall be joint and several with its affiliate which holds those shares pursuant to any such
transfer.

24.4 Unless otherwise provided, shares in Holdco may not be transferred by any Party to any person
so long as any other Party is willing to purchase those shares in the manner provided in this
clause 24. Any Party may agree in writing to waive its pre-emption rights contained in this
Agreement.

24.5 Any Party (Transferor) proposing to transfer any shares in Holdco (Transfer Shares) shall give
notice in writing (Transfer Notice) to Holdco and the other Parties (Continuing Parties), offering
to sell the Transfer Shares to each of the Continuing Parties in proportion (as nearly as may be)
to the number of shares in Holdco held by the Continuing Parties (Proportionate Entitlement).
Every Transfer Notice shall specify: (a) the number of Transfer Shares which the Transferor is
proposing to sell and each of the Continuing Parties’ Proportionate Entitlement; (b) the price at
which the Transferor wishes to sell the Transfer Shares (Transferor’s Price); (c) the other terms
and conditions of the sale of the Transfer Shares (if any) (Prescribed Terms); and (d) the identity
of the person to whom the Transferor proposes to transfer the Transfer Shares (Buyer), and if the
Buyer is a corporation other than a corporation whose shares are listed on a stock exchange, the
place of its incorporation, the name(s) of its legal and beneficial shareholder(s) and the person
who or which ultimately controls or owns the Buyer. Subject as hereinafter mentioned, a Transfer
Notice shall constitute an offer by the Transferor of the sale of the Transfer Shares to the
Continuing Parties at the Transferor’s Price and on the Prescribed Terms (if any). A Transfer
Notice may not be withdrawn except with the written sanction of the directors of Holdco.

24.6

	(a)	 	Each of the Continuing Parties (Purchasing Party) may, within the period of 21 days after
service of a Transfer Notice (Transfer Period), give notice to the Transferor (Purchase
Notice) if it wishes to purchase all (but not part) of its Proportionate Entitlement at the
Transferor’s Price and on the Prescribed Terms (if any) specified in the Transfer Notice and
if applicable, its wish to purchase all (but not part) of the other Continuing Party’s
Proportionate Entitlement at the Transferor’s Price and on the Prescribed Terms (if any)
specified in the Transfer Notice in the event that the other Continuing Party declines to
purchase its Proportionate Entitlement offered by the Transferor under the Transfer Notice.

	(b)	 	If any of the Continuing Parties fails to serve a Purchase Notice before the expiry of the
Transfer Period, it shall be deemed to have declined the offer by the Transferor constituted

Page 16

 

	 	 	by the Transfer Notice. A Purchase Notice shall be irrevocable unless agreed in writing by
the Transferor and all the Continuing Parties serving Purchase Notices.

	(c)	 	If any Continuing Party declines to purchase its Proportionate Entitlement offered by the
Transferor under the Transfer Notice, such Continuing Party’s Proportionate Entitlement shall
be allocated to the other Continuing Party who has applied for the first Continuing Party’s
Proportionate Entitlement.

24.7

	(a)	 	If Purchase Notices are served by the Purchasing Party(ies) for all of the Transfer Shares,
the Transferor shall be bound to sell, and the Purchasing Party(ies) shall be bound to
purchase, all of the Transfer Shares at the Transferor’s Price and upon the Prescribed Terms
(if any) and otherwise in accordance with this clause 24. Completion shall take place within
14 days from the end of the Transfer Period.

	(b)	 	On completion of the sale of the Transfer Shares, the Transferor shall upon receipt of the
Transferor’s Price, transfer the Transfer Shares to the Purchasing Party(ies) by the delivery
of the duly executed transfers in favour of the Purchasing Party(ies) in respect of the
Transfer Shares, together with the relative share certificates and all documents required to
effect the stamping of the transfers (including such statutory declarations, letters,
worksheets and valuations as the tax authorities may require).

24.8 In the event the Transferor fails to carry out the transfer of any Transfer Shares which it
shall have become bound to transfer, the Board of Holdco may authorise some person to execute,
complete and deliver, in the name and on behalf of the Transferor, transfer(s) of the Transfer
Shares to the Purchasing Party(ies) against payment of the Transferor’s Price to Holdco. On payment
of the Transferor’s Price to Holdco, the Purchasing Party(ies) shall be deemed to have obtained a
good quittance for such payment and on execution and delivery of the transfer, the Purchasing
Party(ies) shall be entitled to insist upon its name being entered into the register of members of
Holdco as the holder by transfer of the Transfer Shares. The Purchasing Party(ies) shall procure
that Holdco shall forthwith pay the Transferor’s Price into a separate bank account in the name of
Holdco and shall hold the Transferor’s Price in trust for the Transferor. The Transferor shall in
such case be bound to deliver its certificate(s) for those Transfer Shares, and on such delivery,
shall be entitled to receive the Transferor’s Price, without interest.

24.9 If (a) the Continuing Parties do not wish to purchase all of the Transfer Shares or (b)
through no default on the part of the Transferor, the purchase of the Transfer Shares in respect of
which the Purchase Notice(s) has or have been given shall not be completed within the relevant
period stipulated above, the Transferor shall, at any time within 6 months thereafter, be at
liberty, subject to the Articles and clause 26, to sell and transfer all or any of the Transfer
Shares, to the Buyer (and to no other party) at a price not less than the Transferor’s Price and on
terms not more favourable than the Prescribed Terms (if any) except that the Transferor may provide
representations, warranties, covenants and indemnities customary to such transfer to the Buyer.

24.10 It shall be a condition precedent to the right of the Transferor to transfer shares in Holdco
to any transferee (including an affiliate pursuant to a transfer under clause 24.3) that:

	(a)	 	the Transferor shall transfer to the transferee, and the transferee shall accept the transfer
of, that proportion of all the shareholders’ loans extended by the Transferor to each Group
Company (including the shareholder’s loans (if any) extended by the Transferor to Holdco under
the Amended and Restated Shareholders’ Loan Agreement) and owed to it as at the date of such
share transfer (Transferor’s Loan), equal to the proportion which the number of Transfer
Shares shall bear to the aggregate number of the Transferor’s shares in Holdco immediately
prior to such share transfer. For the avoidance of doubt, the expression transfer of the
Transferor’s Loan and its variations read in the context of this clause 24.10 means the
novation of the Transferor’s Loan (including all rights and obligations of

Page 17

 

	 	 	the Transferor under the Amended and Restated Shareholders’ Loan Agreement) by the
Transferor, the transferee and the relevant Group Company (Relevant Company) pursuant to
which:

	 	(i)	 	the transferee agrees with the Transferor and the Relevant
Company to pay to the Transferor the aggregate amount of the Transferor’s Loan
and any applicable interest thereon outstanding to the Transferor at the date of
the said novation;
	 
	 	(ii)	 	the Relevant Company agrees with the transferee and the
Transferor to repay the Transferor’s Loan aforementioned together with any
applicable interest thereon to the transferee instead of the Transferor; and
	 
	 	(iii)	 	the Transferor shall release and discharge the Relevant Company
from its obligations to repay the Transferor the Transferor’s Loan together with
any applicable interest thereon;

	(b)	 	the other Parties are reasonably satisfied that the transferee is able to carry out its
financing obligations under this Agreement, the Amended and Restated Shareholders’ Loan
Agreement and any other agreement; and

	(c)	 	the transferee (if not already bound by the provisions of this Agreement) executes a Deed of
Ratification and Accession, under which the transferee agrees to be bound by, and shall be
entitled to the benefit of this Agreement as if an original party to this Agreement.

	25.	 	  Transfer of Shares in Holdco Pursuant to Declaration of an Event of Default under
Amended and Restated Shareholders’ Loan Agreement 

25.1 Upon a declaration of the occurrence of an event of default in accordance with and under
clause 12, 13, 14 or 15 of the Amended and Restated Shareholders’ Loan Agreement:

	(a)	 	where there is one Party declaring the occurrence of such event of default, such Party shall
be bound to sell and each of the other two remaining Parties shall be bound to purchase all of
the shares held by the declaring Party in Holdco in proportion to the shareholding percentage
of the remaining Parties in Holdco as between themselves (as nearly as may be) as at the date
of repayment in full of the relevant Loan(s) (as defined under the Amended and Restated
Shareholders’ Loan Agreement) to the declaring Party, at the price of US$1 per share held by
the declaring Party; and

	(b)	 	where there are two Parties declaring the occurrence of such event of default, the two
declaring Parties shall be bound to sell and the one remaining Party shall be bound to
purchase all the shares held by the two declaring Parties in Holdco. The price for the
purchase of shares held by the two declaring Parties shall be determined by Holdco as at the
date of declaration of the occurrence of such event of default and notified in writing by
Holdco to the Parties and shall be a fair and reasonable price certified by the auditors of
Holdco to be the net asset value of Holdco attributable to the relevant shares in Holdco as at
the date of declaration of the occurrence of such event of default and in so certifying, the
auditors shall be considered to be acting as an expert and not as an arbitrator and its
decision, which shall be incorporated in a certificate (a copy of which will be provided to
each of the Parties and Holdco), shall be final and binding on the Parties.

25.2 The relevant price of the sale and purchase of shares under clause 25.1(a) or (b) (as the case
may be) shall be fully satisfied by the remaining Party(ies) by the payment of the amount in cash
or bank draft drawn on a licensed bank in Singapore and made out in favour of the declaring
Party(ies) (at the election of the declaring Party(ies)).

25.3 Completion of the sale and purchase of the shares held by the declaring Party(ies) shall take
place simultaneously with the repayment in full of the relevant Loan(s) to the declaring Party(ies)
in accordance with the Amended and Restated Shareholders’ Loan Agreement.

Page 18

 

25.4 On completion, the declaring Party(ies) shall deliver to the remaining Party(ies):

	(a)	 	duly executed transfer(s) in favour of the remaining Party(ies) or its(their) respective
nominees in respect of all of the shares held by the declaring Party(ies), together with the
relative share certificates and all documents required to effect the stamping of the
transfer(s) (including such statutory declarations, letters, worksheets and valuations as the
tax authorities may require); and

	(b)	 	letters of resignation duly executed by the directors of Holdco and its subsidiaries who are
appointed by the declaring Party(ies).

26. Co-Sale Rights

26.1 In the event that the Transferor after having complied with the provisions of clause 24
desires to transfer any of the Transfer Shares (Co-Sale Shares) to the Buyer, the Transferor shall
give notice in writing to the Continuing Parties of such desire (Co-Sale Notice). The Co-Sale
Notice shall specify the name of the Buyer, the number of Transfer Shares proposed to be
transferred, the price and other terms and conditions of such transfer and enclose an offer
(Co-Sale Offer) dated the date of the Co-Sale Notice made by the Buyer to each of the Continuing
Parties to purchase the shares in Holdco held by such Continuing Party at such time, on the basis
that the number of Co-Sale Shares which the Transferor shall sell, and the number of shares that
such Continuing Party shall sell, shall be pro rata (based on their Shareholding Percentages) of
the number of shares agreed to be purchased by the Buyer, and on terms and conditions (including
price) no less favourable to such Continuing Party than those available to the Transferor. Each
Continuing Party (if it so desires) may accept the Co-Sale Offer made to it by serving on the Buyer
(with a copy to the Transferor) notice in writing of its acceptance within 14 days of the date of
the Co-Sale Offer. The Transferor shall not transfer any of the Transfer Shares to the Buyer unless
it has complied with the provisions of this clause 26.1.

26.2 If any of the Continuing Parties accepts the Co-Sale Offer within the said 14-day period:

	(a)	 	completion of the sale and purchase of the relevant number of shares held by each of the
Transferor and the Continuing Party(ies) shall take place within 7 days following the expiry
of the 14-day period at the registered office of Holdco and on such date within such 7-day
period as the Transferor and the Buyer may agree in writing and notified in writing to the
Continuing Party(ies); and

	(b)	 	the Transferor shall waive its rights of pre-emption in respect of such shares held by the
Continuing Party(ies).

27. Drag Along Rights

Subject to compliance with clause 24 and provided that none of the Continuing Parties exercises its
co-sale rights under clause 26, in the event that the Parties fail to procure a listing of Holdco,
Newco1, Newco2 or Newco3 on a recognised stock exchange within 6 years from the date of this
Agreement and the Buyer wishes to purchase all of the issued share capital in Holdco, the Parties
holding not less than two-thirds of the shares in Holdco (Drag Along Shareholders) shall be
entitled to require the remaining Party(ies) holding not more than one-third of the shares in
Holdco to sell its/their shares to the Buyer (who shall not be an affiliate of any Drag Along
Shareholder) on the same terms and at the same price as that applicable to the shares the Drag
Along Shareholders are selling to the Buyer.

28. Deadlock Resolution 

28.1 A deadlock is deemed to arise in any case where:

Page 19

 

	(a)	 	a Board meeting of any Group Company or a general meeting of Holdco cannot be held for lack
of quorum (determined in accordance with clauses 6.3 and 6.4) after 3 consecutive attempts;

	(b)	 	any matter has been considered by a meeting of the Board of any Group Company or a general
meeting of Holdco for which no resolution has been carried at such meeting in relation to such
matter by reason of an equality of votes for and against any motion dealing with it, and no
agreement can be reached by the Parties in relation to such matter;

	(c)	 	the representatives on any Board Committee fail to reach a unanimous decision on any matter
to be decided by such Board Committee; or

	(d)	 	all Parties (so long as each of them has a Shareholding Percentage of at least 5%) and the
Significant Shareholders fail to reach a unanimous decision on any Reserved Matter.

28.2 In the case of any deadlock, any Party shall be entitled to serve written notice of the
deadlock (Deadlock Notice) on the other Parties.

28.3 If after 30 days from the date of the Deadlock Notice the disagreement is not resolved, each
Party shall within 7 days thereafter appoint a mediator, and the mediators so appointed shall
within a further 21 days mediate between them in negotiations.

28.4 If after 21 days of the appointment of the mediators, the Parties shall still be unable to
resolve the deadlock, then any Party (Deadlock Party) shall, without prejudice to such other rights
and remedies it may have in respect of breaches under this Agreement, be entitled to:

	(a)	 	offer to sell all its shares in Holdco to the other Parties and the provisions of clauses
24.5 (save for sub-paragraph (d)), 24.6, 24.7, 24.8 and 24.10 shall apply mutatis mutandis;

	(b)	 	make an offer to purchase all the shares in Holdco held by the other Parties and the
provisions of clause 28.5 shall apply; or

	(c)	 	(if the other Parties do not agree to purchase the shares in Holdco or, as the case may be,
do not agree to sell the shares in Holdco) serve a dissolution notice in respect of each Group
Company on the other Parties, and thereafter the Parties shall take all such steps as may be
necessary to render each Group Company solvent and to wind up each Group Company voluntarily.

28.5

	(a)	 	The Deadlock Party shall be entitled to give notice (Deadlock Party Notice) to each of the
other Parties and to Holdco offering to purchase all (and not some only of) the shares in
Holdco held by each of the other Parties.

	(b)	 	The price per share offered to be purchased shall be determined by Holdco as at the date of
the Deadlock Party Notice and notified in writing by Holdco to the Parties and shall be a fair
and reasonable price certified by the auditors of Holdco to be the net asset value of Holdco
as at the date of the Deadlock Party Notice. In so certifying, the auditors shall be
considered to be acting as an expert and not as an arbitrator and its decision, which shall be
incorporated in a certificate (a copy of which will be provided to each of the Parties and
Holdco), shall be final and binding on the Parties.

	(c)	 	The Deadlock Party Notice shall specify that the Deadlock Party is offering to purchase all
(and not some only of) the shares in Holdco held by each of the other Parties, request that
Holdco procures that the fair price per share be determined in accordance with sub-paragraph
(b) above and the terms of the offer to purchase (if any) and be expressed to be open for
acceptance for 30 days from the date of service of notification in writing by

Page 20

 

	 	 	Holdco to the Parties of the fair price per share (Offer Period) and be irrevocable without
the written consent of the other Parties.

	(d)	 	Each of the other Parties may, at any time before the expiry of the Offer Period serve a
written notice to the Deadlock Party and Holdco stating whether it wishes to sell all (but not
part) of the shares held by it on the terms set out in sub-paragraph (c) (Acceptance Notice).

	(e)	 	If any of the other Parties fails to serve a notice before the expiry of the Offer Period, it
shall be deemed to have declined the offer to purchase constituted by the Deadlock Party
Notice.

	(f)	 	If Acceptance Notices are served by the other Parties for all the shares held by them in
Holdco, the Deadlock Party shall be bound to purchase and the Parties who served the
Acceptance Notices shall be bound to sell all the shares held by them on the terms set out in
sub-paragraph (c). Completion shall take place within 14 days from the end of the Offer
Period.

	(g)	 	On completion, the Parties who served the Acceptance Notices shall deliver to the Deadlock
Party duly executed transfer(s) in favour of the Deadlock Party or its nominees in respect of
all of the shares held by them, together with the relative share certificates and all
documents required to effect the stamping of the transfer(s) (including such statutory
declarations, letters, worksheets and valuations as the tax authorities may require) and
letters of resignation duly executed by the directors of Holdco and its subsidiaries who are
appointed by the Parties who served the Acceptance Notices.

29. Duration and Termination

29.1 This Agreement shall continue until terminated in accordance with the provisions below.

29.2 This Agreement may be terminated by mutual agreement between the Parties; or (i) automatically
upon the occurrence of an event set out in sub-paragraphs (h), (i) or (j) below, with respect to
all three Parties, (ii) automatically upon the occurrence of an event set out in sub-paragraphs (k)
or (l) below, with respect to the exiting Party only or (iii) by any non-defaulting Party upon the
occurrence of an event set out in sub-paragraphs (a), (b), (c), (d), (e), (f) or (g) below giving
the other Parties written notice of its intention to terminate this Agreement, with respect to the
defaulting Party only (each a Termination Event):

	(a)	 	the insolvency, winding up or presentation of a bankruptcy petition or other insolvency
application against any Party, or a court of competent jurisdiction makes an order, or a
resolution is passed, for the winding up, dissolution or judicial management or administration
of that Party otherwise than in the course of a reorganisation or restructuring previously
approved in writing by the other Parties (such approval not to be unreasonably withheld or
delayed);

	(b)	 	any attachment, sequestration, distress, execution or other legal process is levied, enforced
or instituted against the assets of any Party, or a liquidator, judicial manager, receiver,
administrator, trustee-in-bankruptcy, custodian or other similar officer has been appointed
(or a petition for the appointment of such officer has been presented) in respect of any
assets of that Party;

	(c)	 	any Party convenes a meeting of its creditors or makes or proposes any arrangement or
composition with, or any assignment for the benefit of, its creditors;

	(d)	 	PharmaCo ceases to be a direct or indirect wholly-owned subsidiary of ZPH (or any successor
of ZPH) or an entity that directly or indirectly controls ZPH (or any successor of ZPH) (in
which event TLS and QIV shall be deemed to be the non-defaulting Parties);

Page 21

 

	(e)	 	TLS ceases to be a direct or indirect wholly-owned subsidiary of Temasek Capital (Private)
Limited (or any successor of Temasek Capital (Private) Limited) or an entity that directly or
indirectly controls Temasek Capital (Private) Limited (or any successor of Temasek Capital
(Private) Limited) (in which event PharmaCo and QIV shall be deemed to be the non-defaulting
Parties);
	 
	(f)	 	the undertaking or warranty in clause 23.3 is breached (in which event TLS and PharmaCo shall
be deemed to be the non-defaulting Parties);
	 
	(g)	 	any Party is in material breach of any of its obligations under this Agreement and such
breach, if capable of remedy, is not rectified within 30 days of written notice from any of
the other Parties requiring the rectification of such breach;
	 
	(h)	 	the liquidation of Holdco;
	 
	(i)	 	the listing of Holdco on a recognised stock exchange;
	 
	(j)	 	completion of the sale and purchase of shares under clause 25 following the declaration of
the occurrence of an event of default and repayment of the relevant Loan(s) in accordance with
and under clause 12, 13, 14 or 15 of the Amended and Restated Shareholders’ Loan Agreement
where two or all three Parties declare the occurrence of such event of default;
	 
	(k)	 	completion of the sale and purchase of shares under clause 25 following the declaration of
the occurrence of an event of default and repayment of the relevant Loan(s) in accordance with
and under clause 12, 13, 14 or 15 of the Amended and Restated Shareholders’ Loan Agreement
where any one Party declares the occurrence of such event of default; or
	 
	 
	(l)	 	completion of the sale and purchase of all (and not some only) of the shares in Holdco held
by QIV pursuant to the QIV Put Option or TLS and PharmaCo Call Option.
	For the avoidance of doubt:

	 
	(A)	 	in respect of termination of this Agreement pursuant to a Termination Event set out in
sub-clauses 29.2(a), (b), (c), (d), (e), (f), (g), (k) or (l), only the exiting Party shall
cease to be bound by the terms of this Agreement and the relationship between the remaining
Parties shall continue to be governed by the terms of this Agreement as may be appropriately
amended to reflect a two-party relationship instead of a tripartite relationship;
	 
	(B)	 	termination of this Agreement referred to in sub-paragraph (A) above shall not affect any
accrued rights or interests of any of the Parties under the Primary Transaction Documents
existing immediately prior to the date of such termination; and
	 
	(C)	 	all rights and obligations of the exiting Party and/or its affiliates under the Secondary
Transaction Documents to which the exiting Party and/or any of its affiliates is(are)
party(ies) shall continue for the remaining term of the relevant Secondary Transaction
Documents (where applicable) and remain unaffected by the termination of this Agreement
referred to in sub-paragraph (A) above.

29.3 If a Termination Event set out in sub-clauses 29.2(a), (b), (c), (d), (e), (f) or (g) occurs
in relation to a Party (Affected Party), the Affected Party shall notify the non-defaulting Parties
(Non-Affected Parties) in writing promptly of such Termination Event.

29.4 Each Non-Affected Party shall be entitled to give notice to the Affected Party and to Holdco
within 21 days of the date on which notice is given in accordance with clause 29.3 (or of the date
on which the Non-Affected Party becomes aware of such Termination Event if the Affected Party fails
to give notice in accordance with clause 29.3). The notice under this clause 29.4 shall specify
that the Non-Affected Party:

Page 22

 

(a) is considering exercising its rights under the remaining provisions of this clause 29;

	(b)	 	requests that Holdco procure that the Fair Price (as defined in clause 29.12) of the shares
in Holdco be determined in accordance with clauses 29.11 and 29.12.

29.5 After determination of the Fair Price in accordance with clauses 29.11 and 29.12, which shall
be notified in writing to the Parties by Holdco, any Non-Affected Party (whether or not it gave
notice under clause 29.4) shall be entitled to give notice to Holdco (within 21 days of the date of
the Certificate referred to in clause 29.12) that it wishes to invoke the right to purchase
procedure provided by this clause 29.

29.6 Within 5 days of receipt of the notice under clause 29.5, Holdco shall:

	(a)	 	give notice to the Affected Party of this fact;

	(b)	 	give notice (a Right to Purchase Notice) to each of the Non-Affected Parties of its right to
purchase the shares in Holdco held by the Affected Party (Affected Shares) at the Fair Price,
in each case pro rata to the Shareholding Percentage of the Non-Affected Parties as between
themselves (as nearly as may be) as at the close of business on the date prior to the date of
the Right to Purchase Notice (Entitlement).

29.7 The Right to Purchase Notice shall:

	(a)	 	specify the number of Affected Shares that are offered to each of the Non-Affected Parties
and the price per share in Holdco at which the Affected Shares are offered;

	(b)	 	be expressed to be open for acceptance for 30 days from the date of service of the Right to
Purchase Notice (Right to Purchase Period);

(c) be irrevocable except as set out in clause 29.8; and

(d) be subject to no other terms other than as set out in clause 29.10.

29.8

	(a)	 	Each Non-Affected Party may, at any time before the expiry of the Right to Purchase Period,
serve a written notice upon Holdco:

	 	(i)	 	if applicable, stating its desire to purchase all (but not part)
of the Affected Shares offered to it on the terms set out in clause 29.7; and
	 
	 	(ii)	 	stating if it wishes to purchase the Entitlement of the other
Non-Affected Party in the event that the other Non-Affected Party declines to
purchase its Entitlement constituted by the Right to Purchase Notice.

	(b)	 	If any Non-Affected Party fails to serve a notice before the expiry of the Right to Purchase
Period, it shall be deemed to have declined the right to purchase constituted by the Right to
Purchase Notice.

	(c)	 	A notice served pursuant to clause 29.8 shall be irrevocable without the written consent of
the Affected Party.

29.9 If any Non-Affected Party declines to purchase its Entitlement constituted under the Right to
Purchase Notice, such Non-Affected Party’s Entitlement shall be allocated to the other Non-Affected
Party who has applied for the first Non-Affected Party’s Entitlement.

29.10 Subject only to any regulatory approvals required for effecting a transfer of the Affected
Shares to the Non-Affected Party(ies) or any corporate authorisation required by the Non-Affected

Page 23

 

Party(ies) (Approvals), the Affected Party shall be bound to sell and the Non-Affected Party(ies)
shall be bound to buy the Affected Shares that have been allocated to them or it pursuant to this
clause 29:

	(a)	 	at the Fair Price; and
	 
	(b)	 	within 30 days following the expiry of the Right to Purchase Period.

If any requisite Approval has not been obtained by the date immediately following the expiry of the
said 30-day period referred to in sub-paragraph (b) above, the Right to Purchase Notice shall lapse
and have no further effect.

29.11 The Fair Price for any shares in Holdco (Valuation Shares) shall be determined as at the date
of notification by the Affected Party (or the date on which the Non-Affected Party becomes aware of
the Termination Event if the Affected Party fails to give notice in accordance with clause 29.3)
(Valuation Date).

29.12 The fair price for the Valuation Shares shall be a fair and reasonable price (Fair Price)
certified by the auditors of Holdco to be the net asset value of Holdco attributable to the
relevant shares in Holdco and in so certifying, the auditors shall be considered to be acting as an
expert and not as an arbitrator and its decision, which shall be incorporated in a certificate
(Certificate) (a copy of which will be provided to each of the Parties and Holdco), shall be final
and binding on the Parties.

30. Representations And Warranties 

Each Party represents and warrants to the other Parties as follows:

	(a)	 	it has the power to enter into, exercise its rights and perform and comply with its
obligations under the Primary Transaction Documents;

	(b)	 	it is a company with limited liability duly incorporated and validly existing under the laws
of its jurisdiction of incorporation and it has the power and authority to own assets and to
conduct the business which it conducts and/or purports to conduct;

	(c)	 	all action, conditions and things required to be taken, fulfilled and done (including the
obtaining of any necessary consents) in order (i) to enable it lawfully to enter into,
exercise its rights and perform and comply with its obligations under the Primary Transaction
Documents and (ii) to ensure that those obligations are valid, legally binding and enforceable
have been taken, fulfilled and done;

	(d)	 	the Primary Transaction Documents and all other agreements and instruments executed or to be
executed by it contemplated hereby or thereby will when executed be within its corporate
powers, do not or will not contravene any law or any contractual restriction binding on it or
any provision of its Memorandum and Articles or equivalent constitutive documents in such
other relevant jurisdictions, and are and shall be the legal, valid and binding agreement of
such party, enforceable against such party in accordance with their terms;

	(e)	 	the execution, delivery and performance of the Primary Transaction Documents by it will not
conflict with any law, order, judgment, decree, rule or regulation of any court, arbitral
tribunal or governmental agency, or any agreement, instrument or indenture to which it is a
party or by which any thereof is bound;

	(f)	 	it has received or has had the opportunity to receive legal advice as to the terms and effect
of the Primary Transaction Documents;

Page 24

 

	(g)	 	it and its assets are not entitled to immunity from suit, execution, attachment or other
legal proceedings;

	(h)	 	no legal proceeding, suit or action of any kind whatsoever is current or pending (i) to
restrain the entry into, exercise of any of its rights under and/or performance or enforcement
of or compliance with its obligations under the Primary Transaction Documents or (ii) which
may materially and adversely affect its ability to perform its obligations under any
agreements binding on it; and

	(i)	 	it is solvent, and no steps have been taken or are being taken by it or its shareholders, nor
have any legal proceedings been started or threatened for its dissolution or for the
appointment of a receiver, receiver and manager, or liquidator, judicial manager, trustee or
such other officer in similar capacity to take over it or any of its assets or for its winding
up.

31. Agreement relating to India 

Notwithstanding any other provision in this Agreement, the Parties acknowledge, agree and
undertake, with respect to and in connection with the acquisition of an indirect shareholding in
Innovex (India) Private Limited (IIPL) by each of the Parties and their respective ultimate holding
companies, Temasek Holdings (Private) Limited (Temasek), Interpharma Investments Ltd (Interpharma)
and QTC, pursuant to the Newco3 Put & Call Option Agreement, that:

(1) in the event of any inquiry or investigation or other relevant action (Relevant Action) taken
by the Indian Central Government and/or any relevant regulatory authority in India (including but
not limited to the Foreign Investment Promotion Board (FIPB) and the Reserve Bank of India (RBI))
(Indian Authorities) and/or any third party, including but not limited to (a) the imposition of any
financial levy, penalty or fine on IIPL or its direct or indirect shareholders or (b) a direction
or request to any Party and/or its ultimate holding company to divest its direct or indirect
interest in IIPL, arising solely as a result of a breach by such Party or its ultimate holding
company of the “Guidelines pertaining to approval of foreign/technical collaborations under the
automatic route with previous ventures/tie-ups in India” (Press Notes No. 1 and No. 3, 2005 series)
issued by the Ministry of Commerce & Industry, Government of India (Press Notes), the following
shall apply:

	 	(i)	 	such Party shall respond (and shall procure that its ultimate
holding company responds) either to the Indian Authorities or to IIPL and/or any
Group Company (as relevant) and/or any third party in a timely manner, and shall
furnish any required information in writing or otherwise as required, in order
to facilitate any such inquiry or investigation;
	 
	 	(ii)	 	if the Indian Authorities make a direction or request as set
forth in sub-paragraph (b) above, the Parties shall act together and reasonably
to restructure the Group Companies and their subsidiaries, including the making
of any amendment to any Primary Transaction Document and/or Secondary
Transaction Document, and/or the entering into of any additional agreements, in
order to comply with such direction or request or the Press Notes; and
	 
	 	(iii)	 	such Party shall bear (and shall procure that its ultimate
holding company shall bear) all reasonable costs and expenses (including but not
limited to legal and other professional advisors’ fees and expenses) related to
any such Relevant Action taken by the Indian Authorities and/or any third party,
including all actions required to be taken by any other Party or any Group
Company or subsidiary of any Group Company in compliance with the requirements
of any such Indian Authorities or relevant Press Notes (which for the avoidance
of doubt shall include all reasonable costs and expenses related to any
restructuring set forth in sub-paragraph (ii) above); and

Page 25

 

(2) if requested by PharmaCo at any time, each of QIV and TLS shall unconditionally provide
Interpharma with a written consent and/or a “no objection certificate” in relation to the new
venture or technology agreement or trademark agreement that is in the “same field” (as defined in
the Press Notes), as Zuellig Pharma (India) Private Limited; provided, however, that nothing in
this sub-clause (2), including the giving of any consent or “no objection certificate” pursuant to
this sub-clause (2) shall affect the obligations of PharmaCo and its affiliates under clause 17.

32. Supremacy of this Agreement

Each Party shall use its votes in Holdco and all other means at its disposal so as (a) to ensure
that this Agreement is duly performed and (b) to ensure that the provisions of the Memorandum and
the Articles or equivalent constitutional document of each Group Company are not infringed (save
that, in the event of any conflict between this Agreement and the Memorandum and the Articles of
any Group Company, this Agreement shall prevail as between the Parties).

33. Costs

The costs of and incidental to the incorporation of Holdco and Newco1 shall be borne and paid by
Holdco and Newco1 respectively. Each of the Parties shall pay its own costs incurred in the
preparation and execution of this Agreement.

34. No Partnership or Agency

Nothing in this Agreement shall be deemed to constitute a partnership between the Parties, or
constitute any Party the agent of any of the other Parties for any purpose, or entitle any Party to
commit or bind any of the other Parties (or any of their affiliates) in any manner.

35. Entire Agreement

The Primary Transaction Documents set out the entire agreement and understanding between the
Parties in respect of the joint venture, and supersede all prior oral or written communications,
representations or agreements in relation to the subject matter of this Agreement, which shall
cease to have any further force or effect. It is agreed that:

	(a)	 	none of the Parties has entered into this Agreement in reliance upon any representation,
warranty or undertaking of the other Parties (or any of their representatives or professional
advisers) which is not expressly set out in this Agreement;

	(b)	 	a Party shall have no claim or remedy in respect of misrepresentation (whether negligent or
otherwise) or untrue statements made by the other Parties (or any of its representative or
professional advisers);

	(c)	 	this clause 35 shall not exclude any liability for, or remedy in respect of, fraudulent
misrepresentation.

36. Mutual Consultation and Goodwill

The Parties confirm their intention to promote the best interests of each Group Company and to
consult fully on all matters materially affecting the development of the respective businesses of
each Group Company. Each Party shall act in good faith towards the other Parties in order to
promote the success of each Group Company. Without prejudice to the generality of the foregoing,
the Parties agree to negotiate and discuss in good faith any proposed change in the respective
scope of businesses of any Group Company.

37. Notices

37.1 Any notice or other communication to be given by one Party to the other Parties under, or in
connection with, this Agreement shall be in writing and signed by or on behalf of the Party

Page 26

 

giving it. It shall be served by sending it by fax to the number set out in clause 37.2 or
delivering it by hand or sending it by pre-paid post, to the address set out in clause 37.2, and in
each case marked for the attention of the relevant Party set out in clause 37.2 (or as otherwise
notified from time to time in accordance with the provisions of this clause 37). Any notice so
served by hand, fax or post shall be deemed to have been duly given:

	(a)	 	in the case of delivery by hand, when delivered;
	 
	(b)	 	in the case of fax, at the time of transmission;
	 
	(c)	 	in the case of post, on the second Business Day after the date of posting (if sent by local
mail) and on the seventh Business Day after the date of posting (if sent by air mail),

provided that in each case where delivery by hand or by fax occurs after 6 p.m. on a Business Day,
service shall be deemed to occur at 9 a.m. on the next following Business Day.

References to time in this clause are to local time in the country of the addressee.

37.2 The addresses and fax numbers of the Parties for the purpose of clause 37.1 are as follows:

	 	 	 	 	 
	TLS
	 	 	 	 
	Address

	 	:
	 	60B Orchard Road
	 

	 	 	 	#06-18 Tower 2 The Atrium @ Orchard
	 

	 	 	 	Singapore 238891
	Fax

	 	:
	 	+65 6828 6137
	For the attention of

	 	:
	 	Tan Suan Swee/Derek Lau/Dawn Chan
	 
	 	 	 	 
	PharmaCo
	 	 	 	 
	Address

	 	:
	 	c/o Interpharma Asia Pacific Ltd
	 

	 	 	 	6-8 Harbour Road
	 

	 	 	 	13th Floor Shui On Center
	 

	 	 	 	Wanchai, Hong Kong
	Fax

	 	:
	 	+852 2887 5647
	For the attention of

	 	:
	 	Chief Financial Officer
	 
	 	 	 	 
	QIV
	 	 	 	 
	Address

	 	:
	 	c/o Quintiles Transnational Corp.
	 

	 	 	 	4709 Creekstone Drive
	 

	 	 	 	Durham, NC 27560, United States of America
	Fax

	 	:
	 	+1 919 998 2759
	For the attention of

	 	:
	 	John Russell, Esq., General Counsel

37.3 A Party may notify the other Parties of a change to its name, relevant addressee, address or
fax number for the purposes of this clause 37, provided that, such notice shall only be effective
on:

	(a)	 	the date specified in the notice as the date on which the change is to take place; or

	(b)	 	if no date is specified or the date specified is less than 5 Business Days after the date on
which notice is given, the date following 5 Business Days after notice of any change has been
given.

37.4 In proving such service it shall be sufficient to prove that the envelope containing such
notice was properly addressed and delivered either to the address shown thereon or into the custody
of the postal authorities as a pre-paid recorded delivery, special delivery or registered post
letter, or that the facsimile transmission was made after obtaining in person or by telephone
appropriate evidence of the capacity of the addressee to receive the same, as the case may be.

Page 27

 

38. Assignment

Unless otherwise provided in this Agreement, the rights and obligations of any Party shall not be
assignable or transferable without the consent of the other Parties.

39. Governing Law and Arbitration 

39.1 This Agreement and the relationship between the Parties shall be governed by, and interpreted
in accordance with, the laws of Singapore.

39.2 Any dispute, whether contractual or not, arising out of or in connection with this Agreement
(including any question regarding its existence, validity or termination) shall be referred to and
finally resolved by arbitration in Geneva, conducted in the manner set out below. The UNCITRAL
Arbitration Rules shall govern any arbitration under this clause 39.

39.3 The arbitration tribunal shall consist of 3 arbitrators, one to be appointed by each of the
Parties. The language of the arbitration shall be English.

39.4 Any dispute over the applicability of this clause 39 and/or the UNCITRAL Arbitration Rules
shall be referred to the arbitration tribunal, who shall use best efforts to deliver a decision,
reached without holding an oral hearing if the arbitration tribunal so determines, to resolve the
dispute within 21 days after the matter is referred to it. The decision of the arbitration tribunal
shall be final and binding on the Parties.

39.5 The Parties agree to appoint the International Chamber of Commerce to administrate the
arbitration proceedings.

40. No Rights Under Contracts (Rights of Third Parties) Act (Cap. 53B)

A person who is not a party to this Agreement shall have no right under the Contracts (Rights of
Third Parties) Act (Cap. 53B) to enforce any of its terms.

41. Counterparts

This Agreement may be executed by the Parties in any number of counterparts, each of which is an
original but all of which together constitute one and the same instrument. Any Party may enter into
this Agreement by executing any such counterpart.

42. Further Assurance

Each of the Parties agrees to perform (or procure the performance of) all further acts and things,
and execute and deliver (or procure the execution and delivery of) such further documents, as may
be required by law or as may be necessary to implement and/or give effect to this Agreement and the
transactions contemplated under it.

Page 28

 

SCHEDULE 1

INTERPRETATION

1.1 In this Agreement, unless the context otherwise requires, the following words and expressions
shall bear the following meanings:

	 	 	Amended and Restated Shareholders’ Loan Agreement means the amended and restated
shareholders’ loan agreement dated the same date as this Agreement and made between TLS,
QIV, PharmaCo and Holdco;
	 
	 	 	Articles means, in relation to any Group Company, the Articles of Association of such Group
Company;
	 
	 	 	Board means, in relation to any Group Company, the board of directors of such Group
Company;
	 
	 	 	Business Day means a day (excluding Saturdays, Sundays and public holidays) on which
banks generally are open in Singapore, Hong Kong and the United States for the transaction
of normal banking business;
	 
	 	 	Companies Act means the Companies Act (Cap. 50) of Singapore;
	 
	 	 	Debt/Equity Ratio means, in relation to any Group Company, the ratio of Total External Debt
of such Group Company to Total Shareholder Funds of such Group Company;
	 
	 	 	Deed of Ratification and Accession means the deed in substantially the form set out in the
Exhibit;
	 
	 	 	Group Companies means Holdco, Newco1, Newco2 and (after Newco3 Completion) Newco3;
	 
	 	 	Memorandum means, in relation to any Group Company, the Memorandum of Association of such
Group Company;
	 
	 	 	Net Asset Value means, in relation to any Group Company at any time, the value of the net
assets of such Group Company determined from the latest available audited accounts of such
Group Company as at such time;
	 
	 	 	Newco2 means PharmaLink Asia Pacific Pte. Ltd. (Co. Reg. No. 200500937C), a private limited
company incorporated in Singapore with its registered office at 150 Beach Road, #25-03/04
The Gateway West, Singapore 189720;
	 
	 	 	Newco2 Distribution Agreement has the meaning ascribed to Distribution Agreement in the
Newco2 Put & Call Option Agreement;
	 
	 	 	Newco2 Master Business Transfer Agreement shall have the meaning ascribed to Master
Business Transfer Agreement in the Newco2 Put & Call Option Agreement;
	 
	 	 	Newco2 Services Agreement shall have the meaning ascribed to Services Agreement in the
Newco2 Put & Call Option Agreement;
	 
	 	 	Newco2 Term Loan Facility Agreements shall have the meaning ascribed to Term Loan Facility
Agreements in the Newco2 Put & Call Option Agreement;
	 
	 	 	Newco3 means Innovex Asia Holdings Pte. Ltd. (Co. Reg. No.: 200515117Z), a private limited
company incorporated in Singapore with its registered office at 9 Raffles Place, #32-00
Republic Plaza, Singapore 048619;

Page 29

 

	 	 	Newco3 Master Business Transfer Agreement shall have the meaning ascribed to Master
Business Transfer Agreement in the Newco3 Put & Call Option Agreement;
	 
	 	 	Newco3 Master Services Agreements shall have the meaning ascribed to Master Services
Agreements in the Newco3 Put & Call Option Agreement;
	 
	 	 	Newco3 Term Loan Facility Agreements shall have the meaning ascribed to Term Loan Facility
Agreements in the Newco3 Put & Call Option Agreement;
	 
	 	 	Newcos means Newco1, Newco2 and (after Newco3 Completion) Newco3; and Newco shall be
construed accordingly;
	 
	 	 	Parties means TLS, PharmaCo and QIV; and Party shall be construed accordingly;
	 
	 	 	PharmaLink Business means the business of providing (a) marketing services for patented and
off-patent branded ethical research based pharmaceutical and healthcare products through
agency or contract sales organisation (CSO) arrangements and (b) regulatory services
including advisory services on regulatory environment, activities pertaining to the
registration of patented and off-patent branded ethical research based pharmaceutical and
healthcare products with the relevant regulatory bodies and product licence holding, market
research services and sales and marketing development programmes under the name and style
of “PharmaLink” as an unincorporated business division of ZPH and its affiliates;
	 
	 	 	Primary Transaction Documents means:

	 	(a)	 	this Agreement;
	 
	 	(b)	 	the Amended and Restated Shareholders’ Loan Agreement;
	 
	 	(c)	 	the Supplemented Newco2 Put & Call Option Agreement; and
	 
	 	(d)	 	the Newco3 Put & Call Option Agreement;

	 	 	QIV Put Option means the put option to be granted by TLS and PharmaCo jointly to QIV to
require TLS and PharmaCo to jointly purchase in proportion to their respective Shareholding
Percentage as between themselves (as nearly as may be), the shares held by QIV in Holdco
upon the terms and conditions of the Newco3 Put & Call Option Agreement;
	 
	 	 	QTC means Quintiles Transnational Corp., (Co. Reg. No. 0274393), a corporation incorporated
in North Carolina, United States of America with its principal address at 4709 Creekstone
Drive, Suite 200, Durham, NC 27703, United States of America;
	 
	 	 	Quintiles’ Business means the business providing sales and marketing services in India,
Korea, Australia and New Zealand for ethical research based pharmaceutical products through
contract sales organisation arrangements under the name and style of “Innovex”;
	 
	 	 	Reserved Matters means those matters referred to in Schedule 2;
	 
	 	 	Secondary Transaction Documents means the (a) Newco2 Master Business Transfer Agreement,
Newco2 Term Loan Facility Agreements, Newco2 Services Agreement and Newco2 Distribution
Agreement; and (b) the Newco3 Master Business Transfer Agreement, Newco3 Term Loan Facility
Agreements and Newco3 Master Services Agreements, and includes any such agreement as
amended from time to time;

Page 30

 

	 	 	Shareholding Percentage means, in relation to any shareholder and at any time, the total
number of issued ordinary shares in the capital of Holdco registered in the name of such
shareholder in the share register of Holdco at that time expressed as a percentage of all
the issued ordinary shares in the capital of Holdco held by all the shareholders of Holdco
as at that time;
	 
	 	 	Significant Shareholder means a shareholder of Holdco with a Shareholding Percentage of at
least 15%;
	 
	 	 	Supplemented Newco2 Put & Call Option Agreement means the Newco2 Put & Call Option
Agreement as supplemented by (a) the First Supplemental Agreement and (b) the Second
Supplemental Agreement dated the same date as this Agreement and made between TLS, QIV,
PharmaCo and Holdco;
	 
	 	 	TLS and PharmaCo Call Option means the call option to be granted by QIV to TLS and PharmaCo
jointly to require QIV to sell to TLS and PharmaCo jointly in proportion to their
respective Shareholding Percentage as between themselves (as nearly as may be), the shares
held by QIV in Holdco upon the terms and conditions of the Newco3 Put & Call Option
Agreement;
	 
	 	 	Total External Debt means, in relation to any Group Company, all and any liabilities of, or
amounts due from, or owing by, such Group Company to external non-trade lenders (which, for
the avoidance of doubt, shall exclude the Parties and their affiliates and trade
creditors). All shareholders’ loans extended by the Parties or their affiliates, whether
pursuant to the Amended and Restated Shareholders’ Loan Agreement or otherwise, shall not
be included in the determination of Total External Debt;
	 
	 	 	Total Shareholder Funds means, in relation to any Group Company, the total issued share
capital of such Group Company plus retained earnings minus statutory reserves. All
shareholders’ loans extended by the Parties or their affiliates, whether pursuant to the
Amended and Restated Shareholders’ Loan Agreement or otherwise, shall be included in the
determination of Total Shareholder Funds; and
	 
	 	 	ZPH means Zuellig Pharma Holdings Limited (Co. Reg. No. LL01201), a company incorporated in
Labuan, Malaysia and having its registered office at Brumby House, 1st Floor,
Jalan Bahasa, 87011 Labuan, F.T. Labuan, Malaysia.
	 
	1.2	 	In this Agreement, unless the context otherwise requires:

	 	(a)	 	references to persons shall include individuals, bodies corporate (wherever
incorporated), unincorporated associations and partnerships;
	 
	 	(b)	 	the headings are inserted for convenience only and shall not affect the
construction of this Agreement;
	 
	 	(c)	 	references to times of the day are to local time in Singapore unless
otherwise stated;
	 
	 	(e)	 	references to US$ are to the lawful currency of the United States of America;
	 
	 	(f)	 	words importing the singular number shall include the plural and vice versa;
	 
	 	(g)	 	words importing the masculine gender shall include the feminine and neuter
genders and vice versa;
	 
	 	(h)	 	references to any agreement or document shall include such agreement or
document as amended, varied, novated, supplemented or replaced from time to time;

Page 31

 

	 	(i)	 	any references to parties, clauses, Schedules and the Exhibit are to parties,
clauses, schedules and the exhibit to this Agreement unless otherwise specified;
	 
	 	(j)	 	any reference to an enactment or statutory provision is a reference to it as
it may have been, or may from time to time be modified, consolidated or re-enacted;
	 
	 	(k)	 	references to any legal term used in any applicable jurisdiction (other than
Singapore) for any action, remedy, method or judicial proceeding, legal document,
legal status, court, official or any other legal concept shall be deemed to include
the legal concept which most nearly approximates in Singapore to that legal term;
	 
	 	(l)	 	the word affiliate means, with respect to any person, any other person
controlling, controlled by, or under common control with, such person;
	 
	 	(m)	 	the word control (including its correlative meanings, controlled by,
controlling and under common control with) shall mean, with respect to a corporation,
the right to exercise, directly or indirectly, more than 50% of the voting rights
attributable to the shares of the controlled corporation or control of the composition
of the board of directors of the controlled corporation and, with respect to any
person other than a corporation, the possession, directly or indirectly, of the power
to direct or cause the direction of the management or policies of such person; and
	 
	 	(n)	 	references to a subsidiary shall be construed in accordance with the
Companies Act.

Page 32

 

SCHEDULE 2

RESERVED MATTERS

For the purposes of this Schedule 2 only, Group Companies shall have the meaning ascribed to it in
Schedule 1 as well as including any other direct or indirect subsidiary of Holdco from time to time
established or incorporated.

	(a)	 	Any issue of shares in any Group Company (or securities convertible into shares in such Group
Company), including the number and type of shares or securities to be issued by such Group
Company.

	(b)	 	Any increase, reduction or cancellation of the capital or change in capital structure of any
Group Company (except for an increase in capital pursuant to this Agreement).
	 
	(c)	 	Any alteration to the Memorandum and Articles of any Group Company.

	(d)	 	Any material change in the name of or the nature or scope of the businesses carried on by any
Group Company.

	(e)	 	Any merger or reconstruction exercise undertaken by any Group Company, or any filing by any
Group Company for winding-up, liquidation, receivership or reorganisation under any insolvency
laws or any similar action.

	(f)	 	The formation of any subsidiary of Holdco (other than Newco1, Newco2 and Newco3), Newco1,
Newco2 or Newco3 and the entering into any partnership, joint venture or profit-sharing
agreement by any Group Company.

	(g)	 	The acquisition or disposal by any Group Company of any interest in any company, partnership,
business or other entity (other than the acquisition of shares by Holdco in Newco2 pursuant to
the Supplemented Newco2 Put & Call Option Agreement and the acquisition of shares by Holdco in
Newco3 pursuant to the Newco3 Put & Call Option Agreement).
	 
	(h)	 	Any sale or disposal of the whole or any substantial part of the assets of any Group Company.

	(i)	 	Any Group Company making any acquisition or disposal (including any acquisition or grant of
any licence) of or relating to any intellectual property rights with a value in excess of 5%
of the Net Asset Value of such Group Company or US$500,000, whichever is higher.

	(j)	 	Acquisition by Newco1 of patented and off-patent branded ethical research based
pharmaceutical products and interest in companies that own patented and off-patent branded
ethical research based pharmaceutical products and other investments.

	(k)	 	The creation of any security or encumbrances over any assets of any Group Company with an
aggregate value in excess of 5% of the Net Asset Value of such Group Company or US$500,000,
whichever is higher.

	(l)	 	Any borrowing by any Group Company which would result in the Debt/Equity Ratio of such Group
Company being in excess of 1 : 1 or such other figure as the Parties shall from time to time
determine.

	(m)	 	Any repayment or prepayment of any loan made to any Group Company (other than payments of
loan instalments to banks or financial institutions in the ordinary course of business).

Page 33

 

	(n)	 	Any loan or guarantee made or issued by any Group Company in excess of 2% of the Net Asset
Value of such Group Company or US$500,000, whichever is higher, in a single transaction or 5%
of the Net Asset Value of such Group Company or US$500,000, whichever is higher, in aggregate.

	(o)	 	The entry into of any contract or commitment by any Group Company having a value or likely to
involve expenditure by any Group Company in excess of 2% of the Net Asset Value of such Group
Company or US$500,000, whichever is higher, individually or 5% of the Net Asset Value of such
Group Company or US$500,000, whichever is higher, in aggregate in any one financial year of
such Group Company.

	(p)	 	The commencement, settlement or abandonment of litigation or admission of liability by any
Group Company involving a dispute in excess of 5% of the Net Asset Value of such Group Company
or US$500,000, whichever is higher, (save by Holdco in relation to matters under the (i)
Supplemented Newco2 Put & Call Option Agreement where PharmaCo is the counterparty; and (ii)
Newco3 Put & Call Option Agreement where QIV is the counterparty).
	 
	(q)	 	Approval of the annual budget, business and operating plan of any Group Company.

	(r)	 	The adoption of, or change in, any policy on financial matters (including accounting
practices, depreciation practices, dividends, directors’ fees and remuneration) of any Group
Company, other than those set out in this Agreement.

	(s)	 	Forming policies in relation to the environment and health and safety issues for any Group
Company.

	(t)	 	The approval of, or any material change to, the service or employment contracts of the chief
executive officer and chief financial officer of each Group Company.

	(u)	 	Adopting (or varying) any Group Company’s material policies in respect of employees’
remuneration, employment terms and pension schemes.

	(v)	 	The appointment (and removal) of the chief executive officer and chief financial officer of
any Group Company.
	 
	(w)	 	The appointment (or removal) of the auditors of any Group Company.

	(x)	 	The appointment (or removal) by any Group Company of its representative in respect of
shareholder meetings of companies in which such Group Company has any interest.
	 
	(y)	 	The listing of any Group Company on any recognised stock exchange.

	(z)	 	Any change in the number of directors of any Group Company.

Page 34

 

SCHEDULE 3

EXCLUDED COMPETING BUSINESS (ZPH OR AFFILIATES)

	1.	 	Distribution, logistics, invoicing/collection, data production, importation services,
warehousing, samples and clinical trial samples management;
	 
	2.	 	Toll manufacturing, material sourcing and product development, repackaging and labelling;
	 
	3.	 	Marketing, promotion, sales, merchandising of products to drug stores and modern trade;
	 
	4.	 	Marketing, promotion, sales, merchandising in general practitioner and hospital channels for
non-ethical research based pharmaceutical products;
	 
	5.	 	Provision of services to healthcare providers;
	 
	6.	 	Provision of integrated IT Solutions to third parties including but not limited to principals
and customers;
	 
	7.	 	Real-time sales, inventory;
	 
	8.	 	Market information including but not limited to benchmark data, doctors and customer
databases;
	 
	9.	 	E-commerce/e-transactions hub;
	 
	10.	 	Exclusive data partnerships;
	 
	11.	 	Product licence holding;
	 
	12.	 	Principal Account lines; and
	 
	13.	 	Marketing, promotion, sales and merchandising services which ZPH and/or its subsidiaries
provide(s) to principals under agency or contract sales organisation contracts or arrangements
which are not transferred to Newco2 and/or its subsidiaries by reason of third party consent
being refused or not obtained on terms acceptable to Newco2 within 6 months from completion in
the relevant area pursuant to the Newco2 Master Business Transfer Agreement.

Page 35

 

SCHEDULE 4

EXCLUDED COMPETING BUSINESS (QTC OR AFFILIATES)

	1.	 	Clinical development and related services;
	 
	2.	 	Regulatory advisory services relating to product development; and
	 
	3.	 	Marketing, promotion, sales and merchandising services which QTC and/or its subsidiaries
provide(s) to principals under contract sales organisation contracts or arrangements which are
not transferred to Newco3 and/or its subsidiaries by reason of third party consent being
refused or not obtained on terms acceptable to Newco3 pursuant to the Newco3 Master Business
Transfer Agreement.

Page 36

 

This Agreement has been signed on behalf of the Parties on the date stated at the beginning of the
document.

	 	 	 	 	 	 	 
	SIGNED
By Derek Lau

	 	 	)	 	/s/ Derek Lau	 
	 

	 	 	)	 	 	 
	for and on behalf of

	 	 	)	 	 	 
	TLS BETA PTE. LTD.

	 	 	)	 	 	 
	in
the presence of: Dawn Chan

	 	 	)	 	/s/ Dawn Chan	 
	 
	 	 	 	 	 	 
	SIGNED
By Fritz Horlacher

	 	 	)	 	/s/ Fritz Horlacher	 
	 

	 	 	)	 	 	 
	for and on behalf of

	 	 	)	 	 	 
	PHARMACO INVESTMENTS LTD

	 	 	)	 	 	 
	(formerly known as Transfarma

	 	 	)	 	 	 
	Holdings
Limited) in the presence of: Elaine J. Cheung

	 	 	)	 	/s/ Elaine J. Cheung	 
	 
	 	 	 	 	 	 
	SIGNED
By Ron Wooten, President

	 	 	)	 	/s/ Ron Wooten	 
	 

	 	 	)	 	 	 
	for and on behalf of

	 	 	)	 	 	 
	QUINTILES ASIA PACIFIC

	 	 	)	 	 	 
	COMMERCIAL HOLDINGS, INC.

	 	 	)	 	 	 
	in
the presence of: Eric Green, Assistant Secretary

	 	 	)	 	/s/ Eric Green	 

Page 37

 

THE EXHIBIT

FORM OF DEED OF RATIFICATION AND ACCESSION

     THIS
DEED OF RATIFICATION AND ACCESSION is made on
[§] 200[§] Between:

	(1)	 	[NAME OF TRANSFEREE], a company incorporated in [§] and having its registered office at
[§] (Transferee);

	(2)	 	[NAME OF TRANSFEROR], a company incorporated in [§] and having its registered office at
[§] (Transferor);

	(3)	 	[NAME OF EXISTING PARTY 1], a company incorporated in [§] and having its registered
office at [§]; and

	(4)	 	[NAME OF EXISTING PARTY 2], a company incorporated in [§] and having its registered
office at [§],
	 
	 	 	((3) and (4) collectively referred to as the Existing Parties).

     This Agreement is Supplemental to an Amended and Restated Shareholders’ Agreement
(Agreement) dated 23 January 2006 entered into between TLS Beta Pte. Ltd., PharmaCo
Investments Ltd and Quintiles Asia Pacific Commercial Holdings, Inc., and any and all documents
supplemental thereto. Capitalised terms used in this Deed and not otherwise defined herein shall
have the meaning as are set out for those terms in the Agreement.

Whereas:

(A) The Transferee has agreed to accept the transfer by the Transferor of certain shares in Holdco.

(B) Pursuant to the Agreement, the Transferee is required to execute this Deed as a condition
precedent to the right of the Transferor to transfer shares in Holdco.

Now This Deed Of Ratification And Accession Witnesseth as follows:

1. The Transferee hereby acknowledges that it is in receipt of a copy of the Agreement and is aware
of the terms and conditions therein.

2. The Transferee covenants with the Existing Parties to the Agreement to observe, perform and be
bound by all the terms and conditions of the Agreement [in place of the Transferor] and with effect
from the date on which the Transferee is registered as a shareholder of Holdco, the Transferee
shall be deemed to be a party to the Agreement.

3. Each of the parties covenants with the Transferee that the Transferee shall be entitled to all
the benefit of the terms and conditions of the Agreement as a shareholder to the intent and effect
that the Transferee shall be deemed with effect from the date on which the Transferee is registered
as a shareholder, to be a party to the Agreement.

4. This Deed shall be governed by and construed in accordance with the laws of Singapore, and shall
be enforced in the same manner as provided in the Agreement.

Page 1

 

	 	 	 	 	 	 	 
	The Common Seal of

	 	 	)	 	 	 
	[NAME OF TRANSFEROR]

	 	 	)	 	 	 
	was hereunto affixed in the presence of:

	 	 	)	 	 	 

                                                                                 Director

                                                                                 Director/Secretary

	 	 	 	 	 	 	 
	The Common Seal of

	 	 	)	 	 	 
	[NAME OF TRANSFEREE]

	 	 	)	 	 	 
	was hereunto affixed

	 	 	)	 	 	 
	in the presence of:

	 	 	)	 	 	 

                                                                                Director

                                                                                 Director/Secretary

	 	 	 	 	 	 	 
	The Common Seal of

	 	 	)	 	 	 
	[NAME OF EXISTING PARTY]

	 	 	)	 	 	 
	was hereunto affixed

	 	 	)	 	 	 
	in the presence of:

	 	 	)	 	 	 

                                                                                 Director

                                                                                 Director/Secretary

Page 2exv10w03

 

23 JANUARY 2006

TLS BETA PTE. LTD.

QUINTILES ASIA PACIFIC COMMERCIAL HOLDINGS, INC.

PHARMACO INVESTMENTS LTD

(formerly known as Transfarma Holdings Limited)

ASIA PACIFIC PHARMACEUTICAL HOLDINGS PTE. LTD.

 

AMENDED & RESTATED

SHAREHOLDERS’ LOAN AGREEMENT

 

 

 

CONTENTS

	 	 	 	 	 	 	 
	CLAUSE	 	PAGE
	1.	 	DEFINITIONS AND INTERPRETATION
	 	 	2	 
	1A.	 	AMENDMENT AND RESTATEMENT
	 	 	2	 
	2.	 	THE FACILITIES
	 	 	2	 
	3.	 	AGREEMENT ON PHARMALINK’S OPERATING PROFIT FOR FY2004
	 	 	3	 
	4.	 	AGREEMENT ON QUINTILES’ OPERATING PROFIT FOR FY2004
	 	 	3	 
	5.	 	SHORTFALL LOANS
	 	 	3	 
	6.	 	DRAW DOWN OF FACILITIES
	 	 	3	 
	7.	 	ADJUSTMENTS AND DRAW DOWNS MADE UNDER SHAREHOLDERS’ LOAN AGREEMENT
	 	 	4	 
	8.	 	INTEREST
	 	 	4	 
	9.	 	REPAYMENT
	 	 	4	 
	10.	 	TAXES
	 	 	5	 
	11.	 	REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS
	 	 	6	 
	12.	 	EVENTS OF DEFAULT
	 	 	7	 
	13.	 	PHARMACO EVENT OF DEFAULT
	 	 	9	 
	14.	 	QIV EVENT OF DEFAULT
	 	 	10	 
	15.	 	TLS EVENT OF DEFAULT
	 	 	11	 
	16.	 	REPAYMENT UPON EXERCISE OF QIV PUT OPTION OR TLS AND PHARMACO CALL OPTION
	 	 	12	 
	17.	 	EXPENSES AND STAMP DUTY
	 	 	12	 
	18.	 	ILLEGALITY
	 	 	12	 
	19.	 	WAIVERS, RIGHTS AND REMEDIES
	 	 	13	 
	20.	 	ASSIGNMENT
	 	 	13	 
	21.	 	TIME OF ESSENCE
	 	 	13	 
	22.	 	NOTICES
	 	 	13	 
	23.	 	COUNTERPARTS
	 	 	15	 
	24.	 	GOVERNING LAW AND ARBITRATION
	 	 	15	 
	25.	 	NO RIGHTS UNDER CONTRACTS (RIGHTS OF THIRD PARTIES) ACT (CAP. 53B)
	 	 	16	 
	26.	 	FURTHER ASSURANCE
	 	 	16	 
	 	 	 
	 	 	 	 
	THE SCHEDULE — INTERPRETATION	 	 	17	 

 

 

THIS AGREEMENT is made on 23 January 2006

Between:

	(1)	 	TLS BETA PTE. LTD. (Co. Reg. No. 200500368D), a company incorporated in Singapore and having
its registered office at 60B Orchard Road, #06-18 Tower 2 The Atrium @ Orchard, Singapore
238891 (TLS);

	(2)	 	QUINTILES ASIA PACIFIC COMMERCIAL HOLDINGS, INC. (Co. Reg. No. 807996), a corporation
incorporated in North Carolina, United States of America with its principal address at 4709
Creekstone Drive, Suite 200, Durham, NC 27703, United States of America (QIV);

	(3)	 	PHARMACO INVESTMENTS LTD (Co. Reg. No. LL04247) (formerly known as Transfarma Holdings
Limited), a company incorporated in Labuan, Malaysia and having its registered office at
Brumby House, 1st Floor, Jalan Bahasa, 87011 Labuan, F.T. Labuan, Malaysia (PharmaCo); and

	(4)	 	ASIA PACIFIC PHARMACEUTICAL HOLDINGS PTE. LTD. (Co. Reg. No. 200501108N), a company
incorporated in Singapore and having its registered office at 150 Beach Road, #25-03/04 The
Gateway West, Singapore 189720 (Holdco).

Whereas:

(A) Pursuant to the Shareholders’ Agreement dated 28 January 2005 and made between TLS and PharmaCo
(Shareholders’ Agreement), (i) TLS and PharmaCo have jointly incorporated Holdco; and (ii) Holdco
has incorporated a private limited company in Singapore known as Asia Pacific Pharmaceutical
Investments Pte. Ltd. (Co. Reg. No. 200503853W) with its registered office at 150 Beach Road,
#25-03/04 The Gateway West, Singapore 189720 (Newco1).

(B) Pursuant to the Shareholders’ Loan Agreement dated 28 January 2005 and made between TLS,
PharmaCo and Holdco (Shareholders’ Loan Agreement), TLS and PharmaCo have agreed to extend to
Holdco on demand by Holdco, shareholders’ loans of up to US$150,000,000, comprising cash facilities
of up to an aggregate principal amount not exceeding US$100,000,000, of which up to US$25,000,000
is to be granted by PharmaCo and up to US$75,000,000 is to be granted by TLS (subject to
adjustments). Pursuant to a letter dated 28 December 2005 and made between TLS, PharmaCo and
Holdco (Top Up Loan Letter), the parties have agreed that the loans shall not be subject to
adjustments and PharmaCo shall top up its loan by an additional amount.

(C) Pursuant to the Amended and Restated Shareholders’ Agreement dated the same date as this
Agreement and made between TLS, PharmaCo and QIV (Amended and Restated Shareholders’ Agreement),
TLS, PharmaCo and QIV have agreed that their relationship as shareholders in Holdco shall be
governed by the terms of the Amended and Restated Shareholders’ Agreement.

(D) Under clause 14.1 of the Amended and Restated Shareholders’ Agreement, TLS, PharmaCo and QIV
have agreed to extend shareholders’ loans of up to US$195,000,000 to Holdco.

(E) Pursuant to clause 8.4 of the Put and Call Option Agreement dated 28 January 2005 and made
between PharmaCo, Holdco and TLS (Newco2 Put & Call Option Agreement), as supplemented by the first
supplemental agreement dated 10 November 2005 and made between PharmaCo, Holdco and TLS and the
second supplemental agreement dated the same date as this Agreement and made between PharmaCo,
Holdco, TLS and QIV (Supplemental Agreements), on completion of the sale of all the issued shares
in the capital of Newco2 by PharmaCo to Holdco (Newco2 Completion), Holdco has, as consideration
for the shares in Newco2 purchased by it, allotted and issued to PharmaCo the Newco2 Consideration
Shares (as defined below) and paid to

Page 1

 

PharmaCo the amount of US$50,000,000 which is due and owing
as a debt from Holdco to PharmaCo and treated as a loan from PharmaCo to Holdco under and subject to the terms of this
Agreement (Newco2 Option Consideration Loan).

(F) Pursuant to clause 8.4 of the Put and Call Option Agreement dated the same date as this
Agreement and made between QIV, Holdco, TLS and PharmaCo (Newco3 Put & Call Option Agreement), on
completion of the sale of all the issued shares in the capital of Newco3 (as defined below) by QIV
to Holdco (Newco3 Completion), Holdco will, as consideration for the shares in Newco3 purchased by
it, allot and issue to QIV the Newco3 Consideration Shares (as defined below) and pay to QIV the
amount of US$33,330,000 which shall be due and owing as a debt from Holdco to QIV and treated as a
loan from QIV to Holdco under and subject to the terms of this Agreement (Newco3 Option
Consideration Loan).

(G) This Agreement sets out the terms and conditions upon which TLS, PharmaCo and QIV have agreed
to grant the shareholders’ loans referred to in Recital (D) above.

It is agreed as follows:

	1.	 	Definitions And Interpretation

1.1 Words and expressions used in this Agreement shall have the meanings set out in the Schedule
unless the context requires otherwise.

1.2 The Schedule forms part of this Agreement.

	1A.	 	Amendment And Restatement

1A.1 With effect from the date of this Agreement and subject to clause 1A.2, the Shareholders’ Loan
Agreement and the Top Up Loan Letter shall be amended and restated by replacing them in their
entirety with the terms of this Agreement.

1A.2 Nothing in this Agreement shall affect any accrued rights or interests of the parties under
the Shareholders’ Loan Agreement and Top Up Loan Letter existing immediately prior to the date of
this Agreement.

	2.	 	The Facilities

2.1 Subject to the terms and conditions herein contained, TLS, QIV and PharmaCo shall extend and
make available to Holdco on demand by Holdco, cash facilities of up to an aggregate principal
amount not exceeding US$111,670,000, of which up to US$65,000,000 is to be granted by TLS
(Aggregate TLS Loan), up to US$31,670,000 is to be granted by QIV (QIV Cash Loan) and up to
US$15,000,000 is to be granted by PharmaCo (PharmaCo Cash Loan). An additional loan shall be
required to be extended by PharmaCo (PharmaCo Shortfall Loan) in accordance with clause 5.

2.2 The shareholders’ loans shall be extended by TLS, QIV and PharmaCo in four tranches as follows:

	(a)	 	the first amounts of up to US$50,000,000 demanded by Holdco shall be extended by TLS (First
Tranche TLS Loan);

	(b)	 	in accordance with clause 5, the second tranche demanded by Holdco shall be extended by
PharmaCo and shall comprise the PharmaCo Shortfall Loan;

(c) the third tranche of up to US$16,670,000 demanded by Holdco shall be extended by QIV; and

Page 2

 

	(d)	 	the fourth tranche of up to US$45,000,000 demanded by Holdco shall be extended by TLS, QIV
and PharmaCo equally.

2.3 The parties acknowledge and agree that the Newco2 Option Consideration Loan has been fully
drawn down and is owing from Holdco to PharmaCo (the PharmaCo Cash Loan, Newco2 Option
Consideration Loan and PharmaCo Shortfall Loan are collectively referred to as the Aggregate
PharmaCo Loan).

2.4 The parties acknowledge and agree that upon Newco3 Completion, the Newco3 Option Consideration
Loan shall be treated as fully drawn down and owing from Holdco to QIV (the QIV Cash Loan and
Newco3 Option Consideration Loan are collectively referred to as the Aggregate QIV Loan).

2.5 Holdco shall use the proceeds of the Aggregate TLS Loan, QIV Cash Loan, PharmaCo Cash Loan and
PharmaCo Shortfall Loan:

	(a)	 	to on-lend the same to Newco1 for the purpose of Newco1 acquiring patented and off-patent
branded ethical research based pharmaceutical products or interest in companies which own
patented and off-patent branded ethical research based pharmaceutical products, all
acquisition related expenses (such as legal and due diligence fees), working capital
requirements (such as the purchase of inventory) of Newco1 and transactional expenses of
Newco1; and

	(b)	 	for transactional and operational expenses of Holdco.

2.6 The loans referred to in clause 2.5 from Holdco to Newco1 shall carry such rate of interest (if
any) as TLS, QIV, PharmaCo and Holdco may agree in writing.

	3.	 	Agreement on Pharmalink’s Operating Profit For Fy2004

TLS, PharmaCo and QIV acknowledge and agree that PharmaLink’s Operating Profit for FY2004 as
derived from PharmaLink’s Proforma Financial Statements 2004 is US$3,082,000.

	4.	 	Agreement on Quintiles’ Operating Profit For Fy2004

TLS, PharmaCo and QIV acknowledge and agree that Quintiles’ Operating Profit for FY2004 as derived
from Quintiles’ Proforma Financial Statements 2004 is US$3,255,000.

	5.	 	Shortfall Loan

TLS, PharmaCo and QIV acknowledge and agree that the PharmaCo Shortfall Loan is US$802,950
calculated based on the following formula:

	 	 	 	 	 	 	 
	 

	 	PharmaCo Shortfall Loan =
	 	15.15 x
	 	(US$3,135,000 –
PharmaLink’s Operating Profit for FY2004)
	 

	 	 	 	 	 	 

	6.	 	Draw down of Facilities

6.1 Subject to the provisions under this Agreement, each of the Aggregate TLS Loan, QIV Cash Loan,
PharmaCo Cash Loan and PharmaCo Shortfall Loan may be drawn in such amounts (each a drawing) and at
such times prior to the termination of this Agreement, as Holdco may in its sole discretion
determine provided that:

	(a)	 	no drawings shall be made on the QIV Cash Loan, PharmaCo Cash Loan and the PharmaCo Shortfall
Loan unless and until the First Tranche TLS Loan has been fully drawn by Holdco;

Page 3

 

	(b)	 	the outstanding principal amount of the QIV Cash Loan to be provided by QIV shall not exceed
US$31,670,000 at any time;

	(c)	 	the outstanding principal amount of the PharmaCo Cash Loan to be provided by PharmaCo shall
not exceed US$15,000,000 at any time; and

	(d)	 	the outstanding principal amount of the Aggregate TLS Loan to be provided by TLS shall not
exceed US$65,000,000 at any time.

6.2 When Holdco wishes to make a drawing under this Agreement, it will give TLS, QIV and/or
PharmaCo (as the case may be) notice in writing not later than 3 p.m. (Singapore time) 10 Business
Days prior to that on which the funds are required (or such lesser period as TLS, QIV or PharmaCo
(as the case may be) may agree) specifying the amount of the proposed drawing, the Business Day on
which it is to be made and the bank account to which payment is to be made.

6.3 Any notice under clause 6.2 will be irrevocable and oblige Holdco to borrow the amount stated
on the date stated and will constitute a representation that at the date thereof the
representations and warranties set out in clause 11 are true and correct as though they had been
made at such date and that no Event of Default (which has not been waived in writing by TLS, QIV or
PharmaCo (as the case may be)), nor any event which with the giving of notice and/or the lapse of
time would be an Event of Default, has occurred.

	7.	 	adjustments and draw downs made under shareholders’ loan agreement

7.1 Any adjustments that have been made to the First Tranche TLS Loan and First PharmaCo Loan (as
defined in the Shareholders’ Loan Agreement) under the Shareholders’ Loan Agreement shall be deemed
void and be of no effect on and from the date of this Agreement.

7.2 In the case where any part of the PharmaCo Cash Loan or the Aggregate TLS Loan (as defined in
the Shareholders’ Loan Agreement) has been drawn pursuant to the terms of the Shareholders’ Loan
Agreement (Old Drawings):

	(a)	 	such Old Drawings shall be deemed to be drawn on the loans in the amount and manner set out
in clause 6;

	(b)	 	all interest accrued (if any) in respect of the Old Drawings shall be deemed to have accrued
under the drawings set out in clause 6; and

	(c)	 	where the priority of Old Drawings does not accord with the priority of drawings set out in
clause 6, TLS, QIV or PharmaCo (as the case may be) shall pay the relevant party such amount
to give effect to the priority of drawings set out in clause 6. Any amount payable by TLS, QIV
or PharmaCo (as the case may be) under this clause 7.2(c) to the relevant party shall be made
in cash to a bank account designated by the relevant party within 10 Business Days from the
date of this Agreement.

	8.	 	Interest

The Loans shall carry such rate of interest (if any) as TLS, QIV, PharmaCo and Holdco may agree in
writing.

	9.	 	Repayment

9.1 Subject to clauses 12, 13, 14, 15, 16 and the other provisions hereof, Holdco shall repay the
total amounts drawn down and owing under the Loans in full on the earliest of the following:

(a) upon the joint written demand of TLS, QIV and PharmaCo at any time;

Page 4

 

	(b)	 	upon the written demand of any of TLS, QIV or PharmaCo at any time after the expiry of 5
years after the date of this Agreement, irrespective of whether or not any of the Aggregate
TLS Loan, QIV Cash Loan, PharmaCo Cash Loan and PharmaCo Shortfall Loan has been fully drawn
down; or

	(c)	 	upon the written demand of any of TLS, QIV or PharmaCo at any time after the expiry of 2
years after an initial public offering of the shares in the capital of Holdco, Newco1 or any
company within the Holdco group established or to be established for such purpose.

9.2 Any loan repayment to be made by Holdco pursuant to a demand under clauses 9.1 and 12, shall
where the loan is due to each of TLS, QIV and PharmaCo, be made strictly on a proportionate basis
where the total amount to be repaid by Holdco shall be apportioned between TLS, QIV and PharmaCo
pro rata to the principal amount owing by Holdco to TLS, the principal amount owing by Holdco to
QIV, and the principal amount owing by Holdco to PharmaCo, at the time of repayment.

	10.	 	Taxes

10.1 All sums payable by Holdco under this Agreement shall be paid (a) free of any restriction or
condition, (b) free and clear of and (except to the extent required by law) without any deduction
or withholding on account of any tax and (c) without deduction or withholding (except to the extent
required by law) on account of any other amount, whether by way of set-off or otherwise.

10.2 If:

	(a)	 	Holdco or any other person is required by law to make any deduction or withholding on account
of any such tax or other amount from any sum paid or payable by Holdco to TLS, QIV or PharmaCo
(as the case may be) under this Agreement; or

	(b)	 	TLS, QIV or PharmaCo (as the case may be) (or any person on its behalf) is required by law to
make any deduction or withholding from, or (except on account of tax on the overall net income
of TLS, QIV or PharmaCo (as the case may be)) any payment on or calculated by reference to the
amount of, any sum received or receivable by TLS, QIV or PharmaCo (as the case may be) under
this Agreement:

	 	(i)	 	Holdco shall notify TLS, QIV or PharmaCo (as the case may be) of
any such requirement or any change in any such requirement as soon as it becomes
aware of it;
	 
	 	(ii)	 	Holdco shall pay any such tax or other amount before the date on
which penalties attach thereto, such payment to be made (if the liability to pay
is imposed on Holdco) for its own account or (if that liability is imposed on
TLS, QIV or PharmaCo (as the case may be)) on behalf of and in the name of TLS,
QIV or PharmaCo (as the case may be); and
	 
	 	(iii)	 	the sum payable by Holdco in respect of which the relevant
deduction, withholding or payment is required shall be increased to the extent
necessary to ensure that, after the making of that deduction, withholding or
payment, TLS, QIV or PharmaCo (as the case may be) receives on the due date and
retains (free from any liability in respect of any such deduction, withholding
or payment) a net sum equal to what it would have received and so retained had
no such deduction, withholding or payment been required or made.

10.3 All sums payable to TLS, QIV or PharmaCo (as the case may be) under this Agreement are
exclusive of any goods and services tax or other value added tax (whether imposed in Singapore or
elsewhere) which shall where applicable be paid by Holdco in addition to the sums

Page 5

 

otherwise payable
at the rate in force at the due time for payment or such other time as is stipulated under the
relevant legislation.

	11.	 	Representations, Warranties And Undertakings

11.1 Holdco represents and warrants as follows:

	(a)	 	all necessary corporate and other action has been taken to authorise it to enter into this
Agreement and perform the transactions contemplated under this Agreement, to ensure that those
obligations are legally binding and enforceable and to make this Agreement admissible in
evidence in the courts of Singapore and any other relevant jurisdictions;

	(b)	 	no limit on the borrowing powers of Holdco or its directors will be exceeded as a result of
any drawing made pursuant to this Agreement, and the provisions under this Agreement will
constitute valid, binding and enforceable obligations on Holdco’s part;

	(c)	 	each of Holdco and Newco1 is a company with limited liability duly incorporated and validly
existing under the laws of Singapore and has the power and authority to own assets and to
conduct the business which it conducts and/or purports to conduct;

	(d)	 	the execution, delivery and performance of this Agreement is or will when executed be within
its corporate powers, and do not or will not contravene any law or any contractual restriction
binding on it or any provision of its Memorandum and Articles of Association;

	(e)	 	its entry into, exercise of its rights and/or performance of or compliance with its
obligations under this Agreement do not and will not violate (i) any law to which it is
subject or (ii) any of its constitutive documents (where applicable) or (iii) any agreement to
which it is a party or which is binding on it or its assets, and do not and will not result in
the existence of, or oblige it to create, any security over those assets;

	(f)	 	there is no provision of any existing mortgage, trust deed, contract, licence, franchise,
concession or agreement binding on it which is being contravened or breached by the acceptance
by Holdco of the facilities or the execution by it of this Agreement or by its performance or
observance of any of its obligations hereunder;

	(g)	 	no legal proceeding, suit or action of any kind whatsoever is current or pending (i) to
restrain the entry into, exercise of any of its rights under and/or performance or enforcement
of or compliance with its obligations under this Agreement or (ii) which may materially and
adversely affect its or Newco1’s ability to perform its respective obligations under any
agreements binding on it;

	(h)	 	no Event of Default has occurred or is continuing, and no event or circumstance which, if it
had continued after the giving of any notice, the expiry of any grace period, and/or the
making of any determination by TLS, QIV or PharmaCo provided for in clause 12.2 would become
an Event of Default;

	(i)	 	neither it nor Newco1 is in default in the payment or performance of any of its respective
obligations for borrowed moneys, or in respect of any other liabilities; and

	(j)	 	(i) there is no material adverse change in its or Newco1’s business, management, assets,
financial position or operating environment; and (ii) there are no other conditions which will
materially and adversely affect its ability to perform its obligations under this Agreement,

and each of the representations and warranties in this clause 11.1 shall survive and continue to
have full force and effect after the execution of this Agreement and Holdco hereby warrants that
the above representations and warranties will be true and correct and fully observed until all sums

Page 6

 

outstanding under this Agreement are fully paid and no sums remain to be lent under this Agreement
as if repeated thereby by reference to the then existing circumstances.

11.2 Holdco undertakes to deliver to each of TLS, QIV and PharmaCo a certified copy of a resolution
of Holdco’s board of directors authorising its entry into and performance of this Agreement as soon
as reasonably practicable and in any event within 14 days from the date of this Agreement.

	12.	 	Events of Default

12.1 If at any time and for any reason, whether within or beyond the control of any party to this
Agreement, any of the following events occurs, such an occurrence shall constitute an event of
default by Holdco or Newco1 (as the case may be) (Event of Default) under this Agreement:

	(a)	 	Holdco shall default in the payment of any sum to TLS, QIV or PharmaCo (whether of principal
or any other sums payable under this Agreement);

	(b)	 	Holdco does not use any or all of the Aggregate TLS Loan, QIV Cash Loan, PharmaCo Cash Loan
and PharmaCo Shortfall Loan for the purposes stated under clause 2.5 or for such other purpose
as may be agreed in writing between TLS, QIV and PharmaCo;

	(c)	 	any representation, warranty or statement by Holdco made to TLS, QIV and PharmaCo under this
Agreement is incorrect, untrue or not complied with in any respect;

	(d)	 	Holdco does not perform or comply with any one or more of Holdco’s covenants, conditions or
obligations under this Agreement;

	(e)	 	any other indebtedness in respect of Holdco’s or any indebtedness in respect of Newco1’s
borrowed money, (i) is not paid when due or within any applicable grace period in any
agreement relating to that indebtedness or (ii) becomes (or becomes capable of being
rendered) due and payable before its normal maturity by reason of any actual or potential
event of default or the like (howsoever described) or any facility relating to such
indebtedness is or is declared to be or is capable of being cancelled before its normal expiry
date or any person otherwise entitled to use any such facility is not so entitled;

	(f)	 	it is or will become unlawful for Holdco to perform or comply with any one or more of its
obligations under this Agreement;

	(g)	 	any step is taken by Holdco or Newco1 or any person, an application is made or a petition is
presented or an order is made or a resolution is passed or analogous proceedings are commenced
for the receivership, judicial management, dissolution, liquidation or winding up (whether
voluntary or compulsory) of Holdco or Newco1 (as the case may be);

	(h)	 	Holdco or Newco1 becomes insolvent, is unable to pay its debts as they fall due, stops,
suspends or threatens to stop or suspend payment of all or a material part of Holdco’s or
Newco1’s (as the case may be) debts, begins negotiations or takes any proceeding or other step
with a view to readjustment, rescheduling or deferral of all of Holdco’s or Newco1’s (as the
case may be) indebtedness (or of any part of Holdco’s or Newco1’s (as the case may be)
indebtedness which Holdco or Newco1 (as the case may be) will or might otherwise be unable to
pay when due) or proposes or makes a general assignment or an arrangement or composition with
or for the benefit of Holdco’s or Newco1’s (as the case may be) creditors or a moratorium is
agreed or declared in respect of or affecting all or a material part of Holdco’s or Newco1’s
(as the case may be) indebtedness;

	(i)	 	a distress, attachment, execution or other legal process is levied, enforced or issued on or
against any part of Holdco’s or Newco1’s assets or property;

Page 7

 

	(j)	 	any guarantee of any obligation given by Holdco or Newco1 is not honoured when due and called
upon;

(k) Holdco or Newco1 shall cease or threaten to cease to carry on its business;

	(l)	 	any action, condition or thing (including the obtaining of any necessary consent) at any time
required to be taken, fulfilled or done for any of the purposes stated in clause 11.1(a) is
not taken, fulfilled or done or any such consent ceases to be in full force and effect or any
condition in or relating to any such consent is not complied with;

	(m)	 	any legal proceedings, suit or action of any kind whatsoever (whether criminal or civil) be
instituted against Holdco or Newco1 which in the opinion of TLS, QIV or PharmaCo (as the case
may be) materially and adversely affect the ability of Holdco or Newco1 (as the case may be)
to perform its obligations under any agreements binding on it;

	(n)	 	Holdco or Newco1 is declared by the Minister to be a declared company under the provisions of
Part IX of the Companies Act, Cap. 50;

	(o)	 	a notice or proposal for compulsory acquisition of any of the assets or properties of Holdco
or Newco1 shall be issued or made under or by virtue of an Act of Parliament or other
statutory provision, or if any step is taken by any person or agency with a view to the
confiscation, seizure, compulsory acquisition, expropriation or nationalism of any part of the
assets or property of Holdco or Newco1 (as the case may be);

	(p)	 	this Agreement ceases for any reason or is claimed by Holdco not to be the legal and valid
obligations of Holdco binding upon it in accordance with its terms or this Agreement for any
reason ceases to apply or is claimed by Holdco not to apply to the obligations and the
liabilities therein secured;

	(q)	 	there shall occur (i) a material adverse change in the business, management, assets,
financial position or operating environment of Holdco or Newco1 or (ii) other conditions,
which in the opinion of TLS, QIV or PharmaCo (as the case may be) materially and adversely
affect the ability of Holdco or Newco1 to perform its obligations under any agreements binding
on it;

	(r)	 	Holdco or Newco1 shall commit any material breach or default of its obligations under any
agreements binding on it;

	(s)	 	a deadlock has arisen under clause 28 of the Amended and Restated Shareholders’ Agreement and
is not resolved after the negotiation period of 21 days following the appointment of the
mediators as referred to in clause 28.3 of the Amended and Restated Shareholders’ Agreement;

	(t)	 	any event occurs or circumstances arise which, in the opinion of TLS, QIV or PharmaCo (as the
case may be) (i) gives reasonable grounds for believing that Holdco may not (or may be unable
to) perform or comply with any one or more of Holdco’s obligations under this Agreement or
(ii) has or could have any other material adverse effect on Holdco or Newco1; or

	(u)	 	any event occurs which, under the laws of any applicable jurisdiction, has an analogous or
equivalent effect to any of the events referred to in this clause 12.1.

12.2 Any of TLS, QIV and PharmaCo (each, a Lender) may at any time after the occurrence of an Event
of Default by notice in writing to the other two Lenders (Event of Default Notice) notify them of
the occurrence of an Event of Default. Each of the other two Lenders shall within 10 Business Days
upon receipt of the Event of Default Notice give notice in writing to the first Lender indicating
whether or not it elects to join the first Lender in declaring the occurrence of

Page 8

 

such Event of
Default. If any one or two of the other two Lenders fail(s) to serve such notice upon the expiry of
the aforesaid 10-Business Day period, it (they) shall be deemed to have elected not to join the
first Lender in declaring the occurrence of such Event of Default. The declaring Lender(s) shall
immediately upon expiry of the aforesaid 10-Business Day period by notice in writing to Holdco
declare the occurrence of an Event of Default whereupon:

	(a)	 	any and all amounts outstanding to the declaring Lender(s) under the Loans shall become
immediately due and payable to the declaring Lender(s) without any demand or notice which is
hereby expressly waived;

	(b)	 	the declaring Lender(s) shall be entitled to exercise forthwith all or any of its(their)
respective rights, powers or remedies under this Agreement; and

	(c)	 	any and all of the obligations of the declaring Lender(s) under this Agreement shall be
automatically cancelled (including the commitment of the declaring Lender(s) to extend the
facilities under clause 2.1).

12.3 All payments to be made by Holdco to the declaring Lender(s) under clause 12.2 shall be
applied as follows:

	(a)	 	if there is only one declaring Lender, all payments to be made by Holdco under clause 12.2
shall be made to the declaring Lender; and

	(b)	 	if there are two or three declaring Lenders, all payments to be made by Holdco under clause
12.2 shall be made to the declaring Lenders pro-rata to the amount of Loans owing by Holdco to
the declaring Lenders.

For the avoidance of doubt, the non-declaration of an Event of Default by the non-declaring
Lender(s) shall be without prejudice to the rights of the non-declaring Lender(s) to declare the
occurrence of an Event of Default in respect of such Event of Default or any other Event of Default
at any time.

	13.	 	PharmaCo Event of Default

13.1 If at any time and for any reason, whether within or beyond the control of any party to this
Agreement, PharmaCo or ZPH (as the case may be) commits a material breach of any covenants,
conditions or obligations on its part to be performed and observed under any of the Transaction
Documents to which it is a party, and where such breach is capable of remedy, PharmaCo or ZPH (as
the case may be) shall have failed to remedy such breach to the reasonable satisfaction of TLS and
QIV (i) within the period of 30 days in respect of a breach under any of the Transaction Documents
(except for the Newco2 Distribution Agreement and the Newco2 Services Agreement); or (ii) as soon
as possible, but in any event, no later than 90 days in respect of a breach under the Newco2
Distribution Agreement or the Newco2 Services Agreement, following written notification from TLS
and/or QIV that such breach has occurred, such an occurrence shall constitute an event of default
by PharmaCo (PharmaCo Event of Default) under this Agreement.

13.2 Each of TLS and QIV may at any time after the occurrence of a PharmaCo Event of Default by
notice in writing to the other (PharmaCo Event of Default Notice) notify it of the occurrence of a
PharmaCo Event of Default. QIV or TLS (as the case may be) shall within 10 Business Days upon
receipt of the PharmaCo Event of Default Notice give notice in writing to TLS or QIV (as the case
may be) indicating whether or not it elects to join TLS or QIV (as the case may be) in declaring
the occurrence of such PharmaCo Event of Default. If QIV or TLS (as the case may be) fails to serve
such notice upon the expiry of the aforesaid 10-Business Day period, it shall be deemed to have
elected not to join TLS or QIV (as the case may be) in declaring the occurrence of such PharmaCo
Event of Default. TLS and/or QIV who is(are) the declaring Lender(s) shall immediately upon expiry
of the aforesaid 10-Business Day period by notice in writing to PharmaCo declare the occurrence of
a PharmaCo Event of Default whereupon:

Page 9

 

	(a)	 	any and all amounts outstanding to the declaring Lender(s) under the Loans shall become
immediately due and payable to the declaring Lender(s) without any demand or notice which is
hereby expressly waived;

	(b)	 	the declaring Lender(s) shall be entitled to exercise forthwith all or any of its or their
rights, powers or remedies under this Agreement; and

	(c)	 	any and all of the obligations of the declaring Lender(s) under this Agreement shall be
automatically cancelled (including the commitment to extend the facilities under clause 2.1).

13.3 All payments to be made by Holdco to the declaring Lender(s) under clause 13.2 shall be
applied as follows:

	(a)	 	if only one of TLS or QIV is a declaring Lender, all payments to be made by Holdco under
clause 13.2 shall be made to the declaring Lender; and

	(b)	 	if both TLS and QIV are declaring Lenders, all payments to be made by Holdco under clause
13.2 shall be made to TLS and QIV pro-rata to the amount of Loans owing by Holdco to TLS and
QIV.

For the avoidance of doubt, the non-declaration of a PharmaCo Event of Default by TLS and/or QIV
shall be without prejudice to the rights of TLS and/or QIV to declare the occurrence of a PharmaCo
Event of Default at any time.

	14.	 	QIV Event Of Default

14.1 If at any time and for any reason, whether within or beyond the control of any party to this
Agreement, QIV or QTC (as the case may be) commits a material breach of any covenants, conditions
or obligations on its part to be performed and observed under any of the Transaction Documents to
which it is a party, and where such breach is capable of remedy, QIV or QTC (as the case may be)
shall have failed to remedy such breach to the reasonable satisfaction of TLS and PharmaCo (i)
within the period of 30 days in respect of a breach under any of the Transaction Documents (except
for the Newco3 Master Services Agreements); or (ii) as soon as possible, but in any event, no later
than 90 days in respect of a breach under any of the Newco3 Master Services Agreements, following
written notification from TLS and/or PharmaCo that such breach has occurred, such an occurrence
shall constitute an event of default by QIV (QIV Event of Default) under this Agreement.

14.2 Each of TLS and PharmaCo may at any time after the occurrence of a QIV Event of Default by
notice in writing to the other (QIV Event of Default Notice) notify it of the occurrence of a QIV
Event of Default. PharmaCo or TLS (as the case may be) shall within 10 Business Days upon receipt
of the QIV Event of Default Notice give notice in writing to TLS or PharmaCo (as the case may be)
indicating whether or not it elects to join TLS or PharmaCo (as the case may be) in declaring the
occurrence of such QIV Event of Default. If PharmaCo or TLS (as the case may be) fails to serve
such notice upon the expiry of the aforesaid 10-Business Day period, it shall be deemed to have
elected not to join TLS or PharmaCo (as the case may be) in declaring the occurrence of such QIV
Event of Default. TLS and/or PharmaCo who (is)are the declaring Lender(s) shall immediately upon
expiry of the aforesaid 10-Business Day period by notice in writing to QIV declare the occurrence
of a QIV Event of Default whereupon:

	(a)	 	any and all amounts outstanding to the declaring Lender(s) under the Loans shall become
immediately due and payable to the declaring Lender(s) without any demand or notice which is
hereby expressly waived;

	(b)	 	the declaring Lender(s) shall be entitled to exercise forthwith all or any of its or their
rights, powers or remedies under this Agreement; and

Page 10

 

	(c)	 	any and all of the obligations of the declaring Lender(s) under this Agreement shall be
automatically cancelled (including the commitment to extend the facilities under clause 2.1).

14.3 All payments to be made by Holdco to the declaring Lender(s) under clause 14.2 shall be
applied as follows:

	(a)	 	if only one of TLS or PharmaCo is a declaring Lender, all payments to be made by Holdco under
clause 14.2 shall be made to the declaring Lender; and

	(b)	 	if both TLS and PharmaCo are declaring Lenders, all payments to be made by Holdco under
clause 14.2 shall be made to TLS and PharmaCo pro-rata to the amount of Loans owing by Holdco
to TLS and PharmaCo.

For the avoidance of doubt, the non-declaration of a QIV Event of Default by TLS and/or PharmaCo
shall be without prejudice to the rights of TLS and/or PharmaCo to declare the occurrence of a QIV
Event of Default at any time.

	15.	 	TLS Event of Default

15.1 If at any time and for any reason, whether within or beyond the control of any party to this
Agreement, TLS commits a material breach of any covenants, conditions or obligations on its part to
be performed and observed under any of the Transaction Documents to which it is a party, and where
such breach is capable of remedy, TLS shall have failed to remedy such breach to the reasonable
satisfaction of PharmaCo and QIV within the period of 30 days following written notification from
PharmaCo and/or QIV that such breach has occurred, such an occurrence shall constitute an event of
default by TLS (TLS Event of Default) under this Agreement.

15.2 Each of PharmaCo and QIV may at any time after the occurrence of a TLS Event of Default by
notice in writing to the other (TLS Event of Default Notice) notify it of the occurrence of a TLS
Event of Default. QIV or PharmaCo (as the case may be) shall within 10 Business Days upon receipt
of the TLS Event of Default Notice give notice in writing to PharmaCo or QIV (as the case may be)
indicating whether or not it elects to join PharmaCo or QIV (as the case may be) in declaring the
occurrence of such TLS Event of Default. If QIV or PharmaCo (as the case may be) fails to serve
such notice upon the expiry of the aforesaid 10-Business Day period, it shall be deemed to have
elected not to join PharmaCo or QIV (as the case may be) in declaring the occurrence of such TLS
Event of Default. PharmaCo and/or QIV who (is)are declaring Lender(s) shall immediately upon
expiry of the aforesaid 10-Business Day period by notice in writing to TLS declare the occurrence
of a TLS Event of Default whereupon:

	(a)	 	any and all amounts outstanding to the declaring Lender(s) under the Loans shall become
immediately due and payable to the declaring Lender(s) without any demand or notice which is
hereby expressly waived;

	(b)	 	the declaring Lender(s) shall be entitled to exercise forthwith all or any of its or their
rights, powers or remedies under this Agreement; and

	(c)	 	any and all of the obligations of the declaring Lender(s) under this Agreement shall be
automatically cancelled (including the commitment to extend the facilities under clause 2.1).

15.3 All payments to be made by Holdco to the declaring Lender(s) under clause 15.2 shall be
applied as follows:

	(a)	 	if only one of PharmaCo or QIV is a declaring Lender, all payments to be made by Holdco
under clause 15.2 shall be made to such declaring Lender; and

Page 11

 

	(b)	 	if both PharmaCo and QIV are declaring Lenders, all payments to be made by Holdco under
clause 15.2 shall be made to PharmaCo and QIV pro-rata to the amount of Loans owing by Holdco
to PharmaCo and QIV.

For the avoidance of doubt, the non-declaration of a TLS Event of Default by PharmaCo and/or QIV
shall be without prejudice to the rights of PharmaCo and/or QIV to declare the occurrence of a TLS
Event of Default at any time.

	16.	 	Repayment Upon Exercise of QIV Put Option or TLS and PharmaCo Call Option

QIV may at the completion of the sale and purchase of shares under the QIV Put Option or TLS and
PharmaCo Call Option (QIV Repayment Event) or at any time thereafter by notice in writing declare
the occurrence of a QIV Repayment Event whereupon:

	(a)	 	any and all amounts outstanding to QIV under the Loans shall become immediately due and
payable to QIV without any demand or notice which is hereby expressly waived;

	(b)	 	QIV shall be entitled to exercise forthwith all or any of its rights, powers or remedies
under this Agreement; and

	(c)	 	any and all of the obligations of QIV under this Agreement shall be automatically cancelled
(including the commitment to extend the facilities under clause 2.1).

	17.	 	Expenses And Stamp Duty

Whether or not any of the Aggregate TLS Loan, QIV Cash Loan, PharmaCo Cash Loan and PharmaCo
Shortfall Loan is utilised under this Agreement, Holdco shall pay on a full indemnity basis:

	(a)	 	on demand, all costs and expenses (including legal costs on an indemnity basis) incurred by
TLS, QIV and/or PharmaCo (as the case may be) in protecting or enforcing any of its rights
under this Agreement and/or any such amendment or waiver; and

	(b)	 	promptly, and in any event before any interest or penalty becomes payable, any stamp,
documentary, registration or similar tax payable in connection with the entry into,
registration, performance, enforcement or admissibility in evidence of this Agreement and/or
any such amendment or waiver, and shall indemnify TLS, QIV or PharmaCo (as the case may be)
against any liability with respect to or resulting from any delay in paying or omission to pay
any such tax.

	18.	 	Illegality

18.1 If any change in or introduction of any applicable law, regulation or treaty, or any change in
the interpretation or application thereof, shall make it unlawful under this Agreement for TLS, QIV
or PharmaCo (as the case may be) to make available or fund or maintain any of the Loans or
drawings, TLS, QIV or PharmaCo (as the case may be) shall give notice thereof to Holdco, whereupon
Holdco will repay all amounts outstanding under this Agreement together with any other amounts
payable to TLS, QIV or PharmaCo (as the case may be) under this Agreement within such period as may
be permitted by such law, regulation or treaty, or the change in the interpretation or application
thereof, or, if no such period is stated therein, forthwith.

18.2 If any of the provisions of this Agreement becomes invalid, illegal or unenforceable in any
respect under any law, the validity, legality and enforceability of the remaining provisions shall
not in any way be affected or impaired.

Page 12

 

	19.	 	Waivers, Rights and Remedies

19.1 No failure or delay by any party in exercising any right or remedy provided by law under or
pursuant to this Agreement shall impair such right or remedy or operate or be construed as a waiver
or variation of it or preclude its exercise at any subsequent time and no single or partial
exercise of any such right or remedy shall preclude any other or further exercise of it or the
exercise of any other right or remedy.

19.2 The rights and remedies of any party under or pursuant to this Agreement are several,
cumulative, may be exercised independently of the other parties and as often as such party
considers appropriate and are in addition to its rights and remedies under general law.

	20.	 	Assignment

20.1 Each of TLS, QIV and PharmaCo hereby undertakes to the other parties that in the event it
transfers any of its shares in the capital of Holdco (Transferor) to any person (Transferee), it
shall transfer to the Transferee, and ensure that the Transferee accepts a transfer of, a
proportion of the relevant Loan(s) equal to the proportion which the number of shares the subject
of such transfer shall bear to the aggregate number of shares held by the Transferor in Holdco
immediately prior to such share transfer, in accordance with clause 24.10 of the Amended and
Restated Shareholders’ Agreement Provided that this provision shall not apply to (a) a transfer of
QIV’s shares in Holdco pursuant to the exercise of the QIV Put Option or TLS and PharmaCo Call
Option and (b) a transfer of any party’s shares in Holdco pursuant to clause 25 of the Amended and
Restated Shareholders’ Agreement. In any other case:

	 	(i)	 	any of TLS, QIV and PharmaCo may at its own cost and expense by
giving the other parties and Holdco 7 Business Days’ written notice assign all
or any part of its rights (but not its obligations) under this Agreement,
Provided however that if such assignment is made to a party or parties other
than affiliates of TLS, QIV or PharmaCo (as the case may be), the assigning
party shall first obtain the written consent of the other parties of this
Agreement to the assignment; and
	 
	 	(ii)	 	any of TLS, QIV and PharmaCo may, without the consent of Holdco
but with the written consent of the other parties, transfer all or any part of
its obligations under this Agreement.

20.2 Holdco may not assign all or any part of its rights and/or transfer all or any part of its
obligations under this Agreement without the prior written consent of TLS, QIV and PharmaCo.

20.3 Save as provided in this clause 20, none of the parties shall assign any of its rights and
benefits under this Agreement without the prior written consent of the other parties.

	21.	 	Time Of Essence

Any time or period mentioned in any provision of this Agreement may be extended by mutual agreement
between the parties but as regards any time, date or period originally fixed or any time, date or
period so extended, the aforesaid time shall be of the essence.

	22.	 	Notices

22.1 Any notice or other communication to be given by one party to another under, or in connection
with, this Agreement shall be in writing and signed by or on behalf of the party giving it. It
shall be served by sending it by fax to the number set out in clause 22.2 or delivering it by hand
or sending it by pre-paid post, to the address set out in clause 22.2, and in each case marked for
the attention of the relevant party set out in clause 22.2 (or as otherwise notified from time to
time in accordance with the provisions of this clause 22). Any notice so served by hand, fax or
post shall be deemed to have been duly given:

Page 13

 

	(a)	 	in the case of delivery by hand, when delivered;
	 
	(b)	 	in the case of fax, at the time of transmission; and
	 
	(c)	 	in the case of post, on the second Business Day after the date of posting (if sent by local
mail) and on the seventh Business Day after the date of posting (if sent by air mail),

provided that in each case where delivery by hand or by fax occurs after 6 pm on a Business Day or
on a day which is not a Business Day, service shall be deemed to occur at 9 am on the next
following Business Day.

References to time in this clause are to local time in the country of the addressee.

22.2 The addresses and fax numbers of the parties for the purpose of clause 22.1 are as follows:

	 	 	 	 	 
	(a)

	 	TLS	 	 
	 

	 	Address:
	 	60B Orchard Road
	 

	 	 	 	#06-18 Tower 2 The Atrium @ Orchard
	 

	 	 	 	Singapore 238891
	 

	 	Fax:
	 	+65 6828 6137
	 

	 	For the attention of:
	 	Tan Suan Swee/Derek Lau/Dawn Chan
	 
	 	 	 	 
	(b)

	 	QIV	 	 
	 

	 	Address:
	 	c/o Quintiles Transnational Corp.
	 

	 	 	 	4709 Creekstone Drive
	 

	 	 	 	Durham, NC 27560, United States of America
	 

	 	Fax:
	 	+1 919 998 2759
	 

	 	For the attention of:
	 	John Russell, Esq., General Counsel
	 
	 	 	 	 
	(c)

	 	PharmaCo	 	 
	 

	 	Address:
	 	c/o Interpharma Asia Pacific Ltd
	 

	 	 	 	6-8 Harbour Road
	 

	 	 	 	13th Floor Shui On Center
	 

	 	 	 	Wanchai, Hong Kong
	 

	 	Fax:
	 	+852 2877 5647
	 

	 	For the attention of:
	 	Chief Financial Officer
	 
	 	 	 	 
	(d)

	 	Holdco	 	 
	 

	 	Address:
	 	150 Beach Road#25-03/04
	 

	 	 	 	The Gateway West
	 

	 	 	 	Singapore 189720
	 

	 	Fax:
	 	+65 6396 5710
	 

	 	For the attention of:
	 	Chief Financial Officer
	 
	 	 	 	 
	 

	 	With a copies to:	 	 
	 
	 	 	 	 
	(i)

	 	TLS	 	 
	 

	 	Address:
	 	60B Orchard Road
	 

	 	 	 	#06-18 Tower 2 The Atrium @ Orchard
	 

	 	 	 	Singapore 238891
	 

	 	Fax:
	 	+65 6828 6137
	 

	 	For the attention of:
	 	Tan Suan Swee/Derek Lau/Dawn Chan

Page 14

 

	 	 	 	 	 
	(ii)

	 	QIV	 	 
	 

	 	Address:
	 	c/o Quintiles Transnational Corp.
	 

	 	 	 	4709 Creekstone Drive
	 

	 	 	 	Durham, NC 27560, United States of America
	 

	 	Fax:
	 	+1 919 998 2759
	 

	 	For the attention of:
	 	John Russell, Esq., General Counsel
	 
	 	 	 	 
	(iii)

	 	PharmaCo	 	 
	 

	 	Address:
	 	c/o Interpharma Asia Pacific Ltd
	 

	 	 	 	6-8 Harbour Road
	 

	 	 	 	13th Floor Shui On Center
	 

	 	 	 	Wanchai, Hong Kong
	 

	 	Fax:
	 	+852 2877 5647
	 

	 	For the attention of:
	 	Chief Financial Officer; and

22.3 A party may notify the other parties of a change to its name, relevant addressee, address or
fax number for the purposes of this clause 22 provided that, such notice shall only be effective
on:

	(a)	 	the date specified in the notice as the date on which the change is to take place; or
	 
	(b)	 	if no date is specified or the date specified is less than 5 Business Days after the date on
which notice is given, the date following 5 Business Days after notice of any change has been
given.

22.4 In proving such service it shall be sufficient to prove that the envelope containing such
notice was properly addressed and delivered either to the address shown thereon or into the custody
of the postal authorities as a pre-paid recorded delivery, special delivery or registered post
letter, or that the facsimile transmission was made after obtaining in person or by telephone
appropriate evidence of the capacity of the addressee to receive the same, as the case may be.

	23.	 	Counterparts

This Agreement may be executed by the parties in any number of counterparts, each of which is an
original but all of which together constitute one and the same instrument. Any party may enter
into this Agreement by executing any such counterpart.

	24.	 	Governing Law and Arbitration 

24.1 This Agreement and the relationship between the parties shall be governed by, and interpreted
in accordance with, the laws of Singapore.

24.2 Any dispute, whether contractual or not, arising out of or in connection with this Agreement
(including any question regarding its existence, validity or termination) shall be referred to and
finally resolved by arbitration in Geneva, conducted in the manner set out below. The UNCITRAL
Arbitration Rules shall govern any arbitration under this clause 24.

24.3 The arbitration tribunal shall consist of 3 arbitrators, one to be appointed by each of TLS,
QIV and PharmaCo. The language of the arbitration shall be English.

24.4 Any dispute over the applicability of this clause 24 and/or the UNCITRAL Arbitration Rules
shall be referred to the arbitration tribunal, who shall use best efforts to deliver a decision,
reached without holding an oral hearing if the arbitration tribunal so determines, to resolve the
dispute within 21 days after the matter is referred to it. The decision of the arbitration
tribunal shall be final and binding on the parties.

24.5 The parties agree to appoint the International Chamber of Commerce to administrate the
arbitration proceedings.

Page 15

 

	25.	 	No Rights Under Contracts (Rights of Third Parties) Act (Cap. 53B)

A person who is not a party to this Agreement shall have no right under the Contracts (Rights of
Third Parties) Act (Cap. 53B) to enforce any of its terms.

	26.	 	Further Assurance

Each of the parties agrees to perform (or procure the performance of) all further acts and things,
and execute and deliver (or procure the execution and delivery of) such further documents, as may
be required by law or as may be necessary to implement and/or give effect to this Agreement and the
transactions contemplated under it.

Page 16

 

THE SCHEDULE

INTERPRETATION

In this Agreement and the Schedule, unless the context otherwise requires:

	(i)	 	the following words shall have the following meanings:
	 
	 	 	Business Day means a day (excluding Saturdays, Sundays and public holidays) on which
banks generally are open in Singapore, Hong Kong and the United States for the transaction
of normal banking business;
	 
	 	 	drawings has the meaning given to it by clause 6;
	 
	 	 	FY2004 means financial year ended 31 December 2004;
	 
	 	 	Loans means the Aggregate TLS Loan, Aggregate QIV Loan and Aggregate PharmaCo Loan advanced
or to be advanced by the relevant party to this Agreement or, as the case may be, the
outstanding principal amount of such loans, and a Loan shall be construed accordingly;
	 
	 	 	Newco2 means PharmaLink Asia Pacific Pte. Ltd. (Co. Reg. No. 200500937C), a private limited
company incorporated in Singapore with its registered office at 150 Beach Road, #25-03/04
The Gateway West, Singapore 189720;
	 
	 	 	Newco2 Consideration Shares shall have the meaning ascribed to “Consideration Shares” in
the Newco2 Put & Call Option Agreement;
	 
	 	 	Newco2 Distribution Agreement shall have the meaning ascribed to “Distribution Agreement”
in the Newco2 Put & Call Option Agreement;
	 
	 	 	Newco2 Master Business Transfer Agreement shall have the meaning ascribed to “Master
Business Transfer Agreement” in the Newco2 Put & Call Option Agreement;
	 
	 	 	Newco2 Services Agreement shall have the meaning ascribed to “Services Agreement” in the
Newco2 Put & Call Option Agreement;
	 
	 	 	Newco2 Term Loan Facility Agreements shall have the meaning ascribed to “Term Loan Facility
Agreements” in the Newco2 Put & Call Option Agreement;
	 
	 	 	Newco3 means Innovex Asia Holdings Pte. Ltd. (Co. Reg. No.: 200515117Z), a private limited
company incorporated in Singapore with its registered office at 9 Raffles Place, #32-00
Republic Plaza, Singapore 048619;
	 
	 	 	Newco3 Completion Date means the date on which Newco3 Completion occurs;
	 
	 	 	Newco3 Consideration Shares shall have the meaning ascribed to “Consideration Shares” in
the Newco3 Put & Call Option Agreement;
	 
	 	 	Newco3 Master Business Transfer Agreement shall have the meaning ascribed to “Master
Business Transfer Agreement” in the Newco3 Put & Call Option Agreement;
	 
	 	 	Newco3 Master Services Agreements shall have the meaning ascribed to “Master Services
Agreements” in the Newco3 Put & Call Option Agreement;
	 
	 	 	Newco3 Term Loan Facility Agreements shall have the meaning ascribed to “Term Loan Facility
Agreements” in the Newco3 Put & Call Option Agreement;

Page 17

 

	 	 	PharmaLink Business means the business of providing (a) marketing services for patented and
off-patent branded ethical research based pharmaceutical and healthcare products through
agency or contract sales organisation (CSO) arrangements and (b) regulatory services
including advisory services on regulatory environment, activities pertaining to the
registration of patented and off-patent branded ethical research based pharmaceutical and
healthcare products with the relevant regulatory bodies and product licence holding, market
research services and sales and development programmes under the name and style of
“PharmaLink” as an unincorporated business division of ZPH and its subsidiaries;
	 
	 	 	PharmaLink’s Operating Profit means the earnings before interest and tax of the PharmaLink
Business. It shall be calculated after deducting (a) management fees paid to ZPH and its
subsidiaries engaged in the PharmaLink Business of up to 2% of revenue (with revenue
defined as invoiced sales exclusive of value added tax, goods and services and other
consumption tax); and (b) distribution charges paid to ZPH and its subsidiaries in
connection with the PharmaLink Business. It shall exclude (i) non-recurring extraordinary
or exceptional operating profit including any gains made or losses incurred on disposals of
fixed assets; and (ii) amounts written back for doubtful debts, provisions for obsolescence
or other payables created in periods prior to 1 January 2004;
	 
	 	 	PharmaLink’s Proforma Financial Statements 2004 means the proforma financial statements for
the PharmaLink Business for FY2004, prepared on a basis consistent with the normal basis of
preparation of management accounts, using the same accounting principles, policies and
practices, and, so far as consistent with the foregoing, International Financial Reporting
Standards (or GAAP under which ZPH reports). The proforma financial statements should
reflect all costs of running the business on a stand alone basis;
	 
	 	 	QIV Put Option shall have the meaning ascribed to “Vendor Put Option” in the Newco3 Put &
Call Option Agreement;
	 
	 	 	QTC means Quintiles Transnational Corp. (Co. Reg. No. 0274393), a corporation incorporated
in North Carolina, United States of America with its principal address at 4709 Creekstone
Drive, Suite 200, Durham, NC 27703, United States of America;
	 
	 	 	Quintiles’ Business means the business providing sales and marketing services in India,
Korea, Australia and New Zealand for ethical research based pharmaceutical products through
contract sales organisation arrangements under the name and style of “Innovex”;
	 
	 	 	Quintiles’ Operating Profit means the earnings before interest and tax of Quintiles’
Business. It shall be calculated after (a) including or excluding (as the case may be) a
share of common overhead expenses for shared services in the respective countries in which
Quintiles’ Business is carried on and (b) including information technology support expenses
paid to QTC. It shall exclude (i) non-recurring extraordinary or exceptional operating
profit including any gains made or losses incurred on disposals of fixed assets; and (ii)
amounts written back for doubtful debts, provisions for obsolescence or other payables
created in the periods prior to 1 January 2004;
	 
	 	 	Quintiles’ Proforma Financial Statements 2004 means the proforma financial statements for
Quintiles’ Business for FY2004, prepared on a basis consistent with the normal basis of
preparation of management accounts, using the same accounting principles, policies and
practices, and, so far as consistent with the foregoing, International Financial Reporting
Standards (or GAAP under which QTC reports). The proforma financial statements should
reflect all costs of running the business on a stand alone basis;
	 
	 	 	TLS and PharmaCo Call Option shall have the meaning ascribed to “TLS and PharmaCo Call
Option” in the Newco3 Put & Call Option Agreement;

Page 18

 

	 	 	Transaction Documents means:

	 	(a)	 	(i) this Agreement, (ii) the Amended and Restated Shareholders’ Agreement,
(iii) the Newco2 Put & Call Option Agreement as supplemented by the Supplemental
Agreements and (iv) the Newco3 Put & Call Option Agreement;
	 
	 	(b)	 	the Newco2 Master Business Transfer Agreement, Newco2 Term Loan Facility
Agreements, Newco2 Services Agreement and Newco2 Distribution Agreement; and
	 
	 	(c)	 	the Newco3 Master Business Transfer Agreement, Newco3 Term Loan Facility
Agreements and Newco3 Master Services Agreements,

	 	 	and includes any such agreement as amended from time to time; and
	 
	 	 	ZPH means Zuellig Pharma Holdings Limited (Co. Reg. No. LL01201), a company incorporated in
Labuan, Malaysia and having its registered office at Brumby House, 1st Floor, Jalan Bahasa,
87011 Labuan, F.T. Labuan, Malaysia;
	 
	(ii)	 	references in this Agreement to any party include, where appropriate, that party’s personal
representatives and successors in title;
	 
	(iii)	 	references to persons shall include individuals, bodies corporate (wherever incorporated),
unincorporated associations and partnerships;
	 
	(iv)	 	words importing the singular shall, unless the context otherwise requires, include the plural
and vice versa; and words importing a specific gender shall include the other genders (i.e.
male, female and neuter);
	 
	(v)	 	the headings are inserted for convenience only and shall not affect the construction of this
Agreement;
	 
	(vi)	 	references to a statutory provision shall include such provision and any regulations made in
pursuance thereof as may from time to time be modified or re-enacted whether before or after
the date of this Agreement so far as such modification or re-enactment applies or is capable
of applying to any transactions entered into prior to completion and (so far as liability
thereunder may exist or can arise) shall include also any past statutory provisions or
regulations (as from time to time modified or re-enacted) which such provisions or regulations
have directly or indirectly replaced;
	 
	(vii)	 	references to any legal term used in any applicable jurisdiction (other than Singapore) for
any action, remedy, method of judicial proceeding, legal document, legal status, court,
official or any other legal concept shall be deemed to include the legal concept which most
nearly approximates in Singapore to that legal term;
	 
	(viii)	 	references to any transactions effected on or before completion include the combined result
of two or more transactions, the first of which shall have taken place (or be deemed to have
taken place) or the commencement of which shall have occurred (or be deemed to have occurred)
on or before completion;
	 
	(ix)	 	references to clauses, Recitals and Schedule are to the clauses of, recitals of, and schedule
to, this Agreement;
	 
	(x)	 	references to borrowed money includes any indebtedness (1) for or in respect of money
borrowed or raised (whether or not for cash), by whatever means (including acceptances,
deposits, discounting, factoring, finance leases, hire purchase, sale-and-lease back,
sale-and-repurchase and any form of “off-balance sheet” financing) or (2) for the deferred

Page 19

 

	 	 	purchase price of assets or services (other than goods or services obtained on normal
commercial terms in the ordinary course of trading);
	 
	(xi)	 	a guarantee also includes an indemnity, and any other obligation (howsoever described) of any
person to pay, purchase, provide funds for the payment of, indemnify against the consequences
of default in the payment of, or otherwise be responsible for, any indebtedness of any other
person (and guaranteed shall be construed accordingly);
	 
	(xii)	 	references to indebtedness includes any obligation (whether present or future, actual or
contingent, secured or unsecured, as principal, surety or otherwise) for the payment or
repayment of money;
	 
	(xiii)	 	something having a material adverse effect on a person is to it having a material adverse
effect (1) on its financial condition or business/operations or on the consolidated financial
condition or business/operations of it and its subsidiaries or (2) on its ability to perform
and comply with its obligations under this Agreement;
	 
	(xiv)	 	the word affiliate means, with respect to any person, any other person controlling,
controlled by, or under common control with, such person; and
	 
	(xv)	 	the word control (including its correlative meanings, controlled by, controlling and under
common control with) shall mean, with respect to a corporation, the right to exercise,
directly or indirectly, more than 50% of the voting rights attributable to the shares of the
controlled corporation or control of the composition of the board of directors of the
controlled corporation and, with respect to any person other than a corporation, the
possession, directly or indirectly, of the power to direct or cause the direction of the
management or policies of such person.

Page 20

 

This Agreement has been signed by or on behalf of the parties on the date stated at the beginning
of the document.

	 	 	 	 	 
	SIGNED
By Derek Lau

	 	 	)	   /s/ Derek Lau
	 

	 	 	)	 
	for and on behalf of

	 	 	)	 
	TLS BETA PTE. LTD.

	 	 	)	 
	in
the presence of: Dawn Chan

	 	 	)	   /s/ Dawn Chan
	 
	SIGNED
By Ron Wooten, President

	 	 	)	   /s/ Ron Wooten
	 

	 	 	)	 
	for and on behalf of

	 	 	)	 
	QUINTILES ASIA PACIFIC

	 	 	)	 
	COMMERCIAL HOLDINGS, INC.

	 	 	)	 
	in
the presence of: Eric Green, Assistant Secretary

	 	 	)	   /s/ Eric Green
	 
	SIGNED By Fritz Horlacher

	 	 	)	   /s/ Fritz Horlacher
	 

	 	 	)	 
	for and on behalf of

	 	 	)	 
	PHARMACO INVESTMENTS LTD

	 	 	)	 
	(formerly known as Transfarma Holdings Limited)
	 	 	)	 
	 

	 	 	)	 
	in
the presence of: Elaine J. Cheung

	 	 	)	   /s/ Elaine J. Cheung
	 
	SIGNED
By Derek Lau

	 	 	)	   /s/ Derek Lau
	 

	 	 	)	 
	for and on behalf of

	 	 	)	 
	ASIA PACIFIC PHARMACEUTICAL

	 	 	)	 
	HOLDINGS PTE. LTD.

	 	 	)	 
	in
the presence of: Dawn Chan

	 	 	)	   /s/ Dawn Chan

Page 21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]